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Abstract 
The intracellular transport of proteins and membrane lipids to the cell surface or 
between organelles is a fundamental process in eukaryotic cells.  This process is 
required for the biogenesis and maintenance of organelles, as well as for traffic to the 
cell surface for cell growth and proliferation.  The transport routes in the late secretory 
pathways are branched and complex, and their regulation requires sensing and 
responding to environmental conditions for proper control of cell growth.  Both the 
transport and regulatory mechanisms are robust, so that defects can be overcome by 
alternate mechanisms.  This complexity has made it difficult to identify the late 
exocytic transport machinery and its regulators.  The goal of my thesis work was to 
use a yeast chemical genetic strategy to identify components of the exocytic transport 
machinery, and to generate useful chemical tools that will help us to understand how 
the machinery functions.  I analyzed the effects of small molecules that we obtained in 
two similar high-throughput screens of large libraries of drug-like compounds, in order 
to identify compounds that cause a block in the late exocytic pathway.  Several of our 
new compounds cause exocytic defects and are selectively toxic to yeast mutants in 
which one of numerous transport pathways are blocked.  The design of the high-
throughput screen strategy was based on that of an earlier mutant screen that led to the 
discovery of a novel component of the transport machinery, Avl9, a conserved 
eukaryotic protein that has not yet been well characterized.  Some of our new 
compounds are expected to target Avl9 or proteins with functions related to that of 
Avl9.  In order to identify proteins and processes affected by our compounds, I 
screened for genes which, when overexpressed, can suppress the toxic effects of our 
compounds.  I found that highly-expressed GTR2, which encodes a Ras-family small 
GTPase, can suppress the effects of one of our compounds.  Gtr2 and its paralog and 
binding partner, Gtr1, as well as their metazoan orthologs, signal nutrient availability to 
regulate both traffic and the activity of TOR (target of rapamycin) kinase, a master 
regulator of growth.  Furthermore, the gtr1∆ and gtr2∆ mutants share some 
phenotypes with the avl9∆ mutant.  Our results indicate that our new compounds will 
serve as tools to help us understand how Avl9 and Gtr proteins function in cellular 
response to environmental conditions for proper regulation of protein and membrane 
transport in the late exocytic pathway.  
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Chapter 1
Introduction
! The transport of proteins and membranes between organelles and the cell surface is 
a fundamental process in all eukaryotic cells.  Intracellular transport mediated by 
membrane vesicles and tubules is required to establish and maintain organelle identity 
and function, and also to regulate the components of the cell surface and mediate cell 
growth.  Traffic in the secretory pathway involves a sequence of processes:  proteins 
enter the secretory pathway by means of translocation into the endoplasmic reticulum 
(ER) either co-translationally, or, less commonly, after translation in the cytoplasm (36).  
They are core-glycosylated in the ER and then transported to the Golgi complex where 
they are further glycosylated.  Cargo is then sorted at late Golgi compartments, referred 
to as the trans-Golgi Network (TGN) in most cell types.  Sorting involves recruitment 
into distinct carriers that are targeted to different final destinations: endosomes, 
lysosomes, and the cell surface (6; 8; 39; 43).  Intracellular compartments also receive 
traffic from the cell surface by the endocytic pathway.  
! The molecular mechanisms of transport in the secretory pathway have been 
extensively studied for over 30 years, and much is now known about the basic 
mechanisms of intracellular transport.  Especially well-characterized are the 
mechanisms of transport from the ER, endocytic uptake at the cell surface, and the 
mechanisms of transport vesicle fusion at various stages of transport.  In my thesis 
work, I used the popular experimental model, the budding yeast, Saccharomyces 
cerevisiae, to help understand exocytic transport from endosomes and late Golgi 
compartments.  Exocytic traffic from these compartments is still relatively poorly 
understood, because complex traffic routes have made it difficult to identify the 
molecular machinery that functions in forming the numerous types of late exocytic 
vesicles (25-27).  However, the fundamental mechanisms of transport at each step of the 
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secretory pathway are conserved, and in the first part of this introductory chapter I will 
give an overview of what we know of these mechanisms.  Similar mechanisms, and 
most likely additional processes, are thought to regulate traffic routes in the late 
exocytic pathway.  A long-term goal of my work was to contribute to identifying these 
mechanisms at the Golgi and endosomes.  In addition, it is critical to understand how 
traffic pathways are regulated.  In the second part of this chapter, I describe the traffic 
and signaling pathways that are most relevant for my thesis work.
MECHANISMS OF VESICLE MEDIATED PROTEIN TRANSPORT
Vesicle Coats Recruit Cargo and Form Vesicles 
! Cargo exits from donor compartments by the formation of coated vesicles.  There are 
numerous types of coated vesicles, but three types have been characterized in great 
detail: COPII-coated vesicles, which mediate exit from the ER; COPI (also called 
coatomer)-coated vesicles, which function at various traffic steps but have been 
primarily studied in retrograde transport from the Golgi to the ER; and clathrin-coated 
vesicles, which shuttle between the trans-Golgi network (“late Golgi” in yeast), the 
endsomes, and the plasma membrane (23; 52).
COPII-coated vesicles
! Formation of transport vesicles at the ER requires the recruitment of the small 
GTPase Sar1 by the guanine nucleotide exchange factor (GEF) Sec12 (52; 60).  Sec12 is an 
ER-resident, transmembrane-anchored GEF.  Sar1 associates only with ER membranes.  
After binding of Sar1 to the ER membrane, the GTPase activating protein (GAP) Sec23 
and the cargo recruiter Sec24 form a complex with Sar1 and the cargo. There is only one 
gene for Sec23, and four different Sec24 isoforms are present in mammals (68).  Three 
different Sec24-like genes are encoded in the yeast genome, which suggests that 
different types of cargo might associate with different Sec24 recruiters, and that 
different isoforms mediate transport of subsets of cargo (61). Finally, a subcomplex of 
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Sec13/31 binds to the cargo-associated Sec23/24 complex. The Sec13/31 complex helps 
to deform the membrane and to stabilize the polymerizing coat.  Sec13/31 can even 
assemble into a cage-like form in the absence of the other components of the COPII coat 
(62).  After the vesicle is formed, the coat is released upon hydrolysis of GTP to GDP by 
Sar1.
COPI-coated vesicles 
! The process of COPI vesicle biogenesis is controlled by Arf1, a small GTPase of the 
Ras superfamily.  However, unlike Sar1 in COPII vesicle biogenesis, Arf1 can induce 
vesicle formation at multiple distinct membranes along the secretory pathway, and it 
can recruit both COPI coat components and adaptor complexes of the clathrin coat (61).  
A variety of guanine nucleotide exchange factors (GEFs) are involved in the recruitment 
of Arf1 to different membranes.  All Arf GEFs share a domain with the first Arf GEF that 
was discovered, Sec7 (11).  This domain is required to induce the exchange of bound 
GDP to GTP in Arf1.  GBF1, a large Sec7-domain-containing GEF, is the major exchange 
factor involved in COPI vesicle biogenesis (40). 
! Following nucleotide exchange, Arf1-GTP undergoes conformational change, 
leading to the exposure of a myristoylated N-terminal amphipathic helix that provides 
stable membrane anchorage (35). Then, Arf1-GTP recruits coatomer to the membrane.  
Coatomer components in turn recruit cargo proteins.  After the formation of a COPI-
coated vesicle, the coat has to be released to allow for vesicle fusion with the target 
membrane.  The uncoating reaction depends on GTP hydrolysis by Arf1 (65), catalyzed 
by Arf1 GTPase-activating proteins (ArfGAPs).  In addition to recruiting and releasing 
coatomer, an Arf- GEF/GAP- mediated cycle of GTP exchange and hydrolysis was 
proposed to play a role in regulating the uptake of cargo into COPI vesicles (34).
Clathrin-Coated vesicles   
! Clathrin-coated vesicles can form at different compartments in the late secretory 
pathway and in the endocytic pathway: the trans-Golgi network, endosomes, and the 
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plasma membrane. The clathrin coat consists of an assembly of clathrin triskelions, 
which are formed from three clathrin heavy chains and three clathrin light chains.  
Besides clathrin, the various types of clathrin-coated vesicles contain one of four 
adaptor protein (AP) complexes (AP1–AP4) and additional adaptor-like proteins, which 
are involved in the recognition and recruitment of cargoes (45).  Similar to COPI, the 
formation of clathrin-coated vesicles requires the small GTPase, Arf1, for the 
recruitment of adaptor subunits, which then recruit cargo and clathrin.  The best-
characterized clathrin-coated vesicles function in endocytic uptake and contain the AP2 
adaptin complex.  In contrast, the AP1 adaptor-containing clathrin-coated vesicles 
mediate transport between the Golgi and endosomes, possibly in both directions (45).  
The functions of the other two adaptin complexes are less clear: AP3 promotes the 
delivery of proteins to lysosomes, and also appears to function in the formation of 
regulated secretory granules (2; 58), while AP4 may mediate a pathway to the plasma 
membrane (55). 
! The budding and release of clathrin-coated vesicles involves the mechanochemical 
action of dynamin GTPases (13; 28) as well as various BAR domain proteins that 
directly modify membrane curvature either at the plasma membrane or at the TGN/
endosomes; these include endophilin, amphiphysin, nexins, and epsins (9; 19-20; 64).  
Actin and its regulators also play critical roles in clathrin coated vesicle formation, both 
at the plasma membrane and at the TGN (10; 18).
Other vesicle coats  
! Although COPI, COPII, and clathrin-coated vesicles have been studied the longest 
and are therefore best characterized, there are other types of vesicles.  For example, the 
retromer is a coat complex that mediates traffic from endosomes back to the Golgi (4).  
Other coats, especially those that traffic cargo to the cell surface, may be specialized to 
select only certain types of cargo as a mechanism to regulate what gets transported to 
the cell surface, as well as when and where transport occurs.  These coats likely 
diverged significantly between distant species or cell types that need to traffic different 
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cargo to the cell surface.  For example, a specialized vesicle coat recognizes and 
transports chitin synthase Chs3 and a few other proteins to the bud neck region of yeast. 
This transport is dependent on Arf1p and a protein complex called exomer (51; 66).  
Metazoans do not contain proteins that are readily identifiable as homologs of the 
exomer components.  It is therefore possible that there are diverse coat complexes with 
unique cargo specificities and overlapping functions, which makes it difficult to identify 
the coat proteins involved in transport to the cell surface.
Vesicle Targeting and Fusion
Rab GTPases regulate vesicle targeting
Rab GTPases are central regulators of membrane traffic.  Like Arf and Sar1, Rab 
proteins are members of the Ras superfamily of small GTPases that function as 
molecular switches.  Rab proteins form the largest family of small GTPases, and there 
are more than 60 Rab GTPases in mammalian cells.  As for the other GTPases, Rabs 
alternate between two conformational states: the GTP-bound “on” form and the GDP-
bound “off” form.  The exchange of GDP for GTP is catalyzed by guanine nucleotide 
exchange factors (GEFs), which therefore regulate the activation of the GTPases.  The 
primary function of Rab proteins is to ensure that cargoes are delivered to their correct 
destinations.  They do this by controlling various aspects of transport, including vesicle 
budding, uncoating, motility, and fusion.  Rabs play a role in regulating a wide range of 
effector proteins such as sorting adaptors, tethering factors, kinases, phosphatases, and 
cytoskeletal motors (42; 63).  The effectors are usually activated or recruited by the GTP-
bound form of the Rab protein.  Conversion from the GTP- to the GDP-bound form is 
driven not only by the intrinsic GTPase activity of the Rab protein but is also catalyzed 
by GAPs (GTPase activator proteins).  Rab GDI (GDP dissociation inhibitor) prevents 
release of GDP from Rab, thus stabilizing the GDP –bound form (63).   
! The first characterized function of Rab proteins was the regulation of membrane 
vesicle fusion with the appropriate target membrane.  This conclusion was made from 
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the observation that yeast cells with a mutant allele of the Rab GTPase, Sec4, 
accumulate post-Golgi exocytic vesicles that cannot fuse with the plasma membrane 
(49).  This phenotype suggested that Rab GTPases might mediate vesicle docking or 
fusion.  It was later shown that key effectors for Rab proteins are tethering complexes 
that form contacts between the transport vesicle and the acceptor membrane.  In its 
GTP-bound form, Sec4 interacts with Sec15, a subunit of the octameric exocyst tethering 
complex on the plasma membrane (24).  Tethering complexes on other target 
membranes are effectors for Rab proteins that regulate targeting to those membranes.  
For example, EEA1 is an effector for Rab5 in regulating fusion with early endosomes 
(12).  Different Rab GTPases are localized to distinct organelles, which is another reason 
that Rab GTPases were initially suspected of playing a role in regulating membrane 
targeting.  In some cases, in particular early endosomes, different Rab proteins are 
located on the same organelle but reside in distinct membrane microdomains (63).
SNARE proteins mediate specific membrane fusion
! Both to maintain organelle identity and to regulate the specificity of traffic, it is 
critical for membrane fusion to occur in a controlled manner.  The key proteins 
responsible for membrane fusion also play a role in specifying membrane identity.  
These are the SNARE proteins.  The initials stand for soluble N-ethylmaleimide-
sensitive factor attachment protein receptors).  SNAREs were identified in a search for 
membrane receptors that bind SNAPs (soluble NSF attachment proteins) and NSF 
(Nethylmaleimide-sensitive factor) (37; 59).  SNAREs have been classified as v- and t-
SNAREs, because they operate on opposing membranes, usually on a transport vesicle 
(v-SNARE) and a target membrane (t-SNARE).  Tethering factors such as the exocyst act 
over a longer distance to “capture” the transport vesicles, and this facilitates the 
subsequent pairing of the v-SNARE with the cognate t-SNARE.  The assembly of 
specifically matched v-/t-SNAREs between two membranes generates SNARE 
complexes that bring the lipid bilayers close together and drive membrane fusion (1;29; 
31; 69).  In order to allow subsequent rounds of transport, the SNARE complex needs to 
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be disassembled.  This is catalyzed by the combined action of alpha-SNAP and NSF (46; 
72).
! Specific SNARE proteins are present on specific membranes, and this helps to 
regulate proper targeting and fusion.  However, SNARE’s can potentially pair 
inappropriately, so there are additional regulators of SNARE-mediated fusion.  Key 
regulators of SNARE complex assembly are Sec1/Munc18-like (SM) proteins (54) .  In 
regulated exocytosis such as synaptic vesicle fusion, SM proteins are important targets 
of regulatory proteins.  Additional regulators of membrane fusion include the Ca2+-
binding synaptotagmins (73), and complexins, which either inhibit or facilitate SNARE 
action (38).
Membrane Lipids Regulate Traffic
! The control of membrane lipid composition is critical for regulating essentially all 
aspects of membrane trafficking.  For example, compartment-specific recruitment of 
components of the traffic machinery, including both coat components and tethering 
factors, involves localized generation of specific phosphoinositides (PIs) (14). These 
various PIs are generated by the phosphorylation of the hydroxyl groups at the 3, 4 and 
5 carbon positions of the inositol ring of phosphatidylinositol (PtdIns).  This process is 
mediated by various PI kinases and PI phosphatases (57).  An additional mechanism by 
which membrane composition regulates traffic is cargo recruitment into sterol-rich 
“lipid rafts” (33; 56).  Furthermore, lipid modification is important for deforming 
membranes during vesicle budding and pinching off (5).
Summary
! Exocytic trafficking from the Golgi and endosomes is expected to involve all of the 
mechanisms reviewed here:  1) recruitment of cargo proteins via lipid-mediated 
enrichment and coat proteins; 2) shaping of the vesicle by coats, lipid-modifying 
enzymes and the cytoskeleton; 3) pinching off the vesicles by the action of dynamin 
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GTPases, the cytoskeleton, and motor proteins, and lipid-modifying enzymes; 4) 
specific targeting and fusion with the plasma membrane, at least in some cases via an 
endosomal intermediate.  The results and tools generated from my thesis work promise 
to help identify components of this machinery in the late secretory pathway. 
TRAFFIC PATHWAYS AND SIGNALING PATHWAYS IN POST-GOLGI TRANSPORT
! Defining the traffic routes in the late exocytic pathways, and understanding the 
intracellular signaling mechanisms that regulate these pathways, is essential for a 
fundamental understanding of intracellular transport.  The amount and direction of 
traffic from the Golgi and endosomes must be modulated, and the regulation of this 
process is not well understood.  Much of this regulation occurs at the level of 
endosomes, which receive signals that indicate the nature of the extracellular 
environment as well as signals that indicate the cell’s state, for example the amount of 
various nutrient reserves.  The cell integrates these signals for optimizing the type of 
cargo, and cargo quantity, to be trafficked to the cell surface, maintained in the 
endosomes/Golgi, or trafficked to the lysosome either for a function there or for 
degradation.  In particular, regulation of traffic to the cell surface is critical for proper 
control of cell growth and proliferation.  The following review on traffic pathways in 
yeast will provide background to help explain the rationales behind the design of my 
thesis work, while a section on signaling will provide background for interpreting some 
of my results. 
 
Branching in the Late Secretory Pathway
In both yeast and mammalian cells, secretory cargoes are transported to the cell 
surface by at least two pathways (25; 39).  In yeast, secretory vesicles that accumulate in 
the late sec mutants, such as sec6-4, can be separated into two vesicle species based on 
their different buoyant densities and unique cargoes (25).  The lighter vesicles transport 
surface proteins, such as the cell wall protein Bgl2p, which contribute to cell growth, 
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while the denser vesicles transport invertase and other enzymes secreted into the 
periplasm or growth medium (25).  The existence of two pathways helps to explain why 
it is difficult to isolate mutants that are defective in the late secretory pathway.  A 
mutation that causes a defect in just one of the transport pathways from the Golgi may 
not be sufficient to display an obvious phenotype, because cargoes can be diverted from 
the blocked route so that cells are still viable.  Therefore, it is necessary to screen for 
mutants with defects in the late exocytic pathway by using a mutant strain background 
that already has a defect in one pathway, so that an additional mutation can generate a 
screenable phenotype (26-27).  As described at the end of this chapter, my thesis work 
included a chemical-genetic version of a successful mutant screen that was performed 
in such a strain background.  The mutant screen and chemical screen have identified 
genes and chemical tools that will help us to understand the mechanisms and 
regulation of late exocytic transport (27; 71). 
Multiple Traffic Pathways Require VPS (Vacuolar Protein Sorting) Gene Function 
VPS proteins function in traffic to the vacuole
! The yeast vacuole is analogous to mammalian lysosomes, but it has additional 
functions.  It is involved in many processes, including protein turnover, osmolarity 
regulation, pH homeostasis, and nutrient storage.  The VPS (vacuolar protein sorting) 
proteins are involved in the transport of cargo from the Golgi to the vacuole (reviewed 
in (7)).  A model cargo in this pathway, carboxypeptidase Y (CPY), is sorted at the Golgi 
by being diverted away from the exocytic pathway and recruited into vesicles that 
deliver it to endosomes called the prevacuolar compartment (PVC), from which it is 
transported to the vacuole.  The proper sorting and processing of CPY is used in assays 
to study VPS protein function.  The vps mutants were isolated by screening for mutants 
that secrete CPY from the cell (3; 44; 48).  The mutants were divided into six classes (A to 
F) based on a number of criteria including vacuolar morphology and the secretion of 
CPY.  For example, mutants in Class E accumulate an exaggerated form of the PVC 
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endosomes in which most CPY gets trapped.  Most of the VPS proteins, including those 
in the Class E, have mammalian homologs with similar functions.
! Among the VPS proteins, only a few have been implicated in the formation of 
vesicles from the Golgi.  One of these proteins, which is very relevant to my thesis work, 
is Vps1.  The VPS1 gene encodes a homolog of the metazoan protein, dynamin (41; 47).  
Unlike some dynamins, Vps1 appears not to be involved in endocytosis, but is instead 
proposed to function at the Golgi and/or endosomes.  In the vps1∆ mutant, CPY is 
secreted, and vacuolar membrane proteins are transported to the plasma membrane 
rather than the vacuolar membrane (41).  Clathrin has also been found to be involved in 
the formation of the vesicles that transport vacuolar proteins from the Golgi (16).  As in 
vps mutants, a temperature-sensitive mutant of clathrin results in the mislocalization of 
vacuolar proteins to the cell surface (53).
 
VPS proteins function in an exocytic pathway
! In addition to functioning in traffic to the vacuole, VPS proteins also play a role in 
traffic in one branch of the exocytic pathway (26).  For example, in the vps1∆ mutant, 
exocytic cargo such as invertase is missorted from high-densitiy secretory vesicles and 
is instead trafficked in low-density vesicles along with cargo normally in low-density 
vesicles, such as Bgl2.  Thus, only one of the known exocytic pathways appears to be 
functional in the mutant, and all cargo is transported in this pathway (26).  Similarly, 
clathrin is involved in transporting the cargo secreted by dense vesicles (21; 26).  These 
findings suggest that exocytic cargo normally transported by high-density exocytic 
vesicles are transported together with vacuolar hydrolases from the Golgi to an 
endosomal compartment by clathrin-coated vesicles, and from endosomes, cargo is 
sorted either to the vacuole or to the cell surface.  When the Golgi-to-endosome route is 
blocked in vps mutants, both invertase and CPY are missorted into light-density 
exocytic vesicles.  These finding were crucial for the design of genetic screens aimed at 
identifying components of the late exocytic transport machinery.
10
A Classical Genetic Screen Strategy for Identifying Genes Involved in Post-Golgi 
Transport
! As I discussed earlier, the branching of the post-Golgi pathway makes it important 
to screen for mutants involved in the late secretory process using a strain background 
that already has a secretion defect.  Blocking a remaining pathway by an additional 
mutation in a second gene is then expected to result in lethality.  The genetic interaction 
between the two genes that together are required for viability is called “synthetic 
lethality.”  In yeast, ~ 70% of the genes are non-essential under optimal growth 
conditions, but when these genes are deleted in combination with a deletion of another 
non-essential gene, together the two deletions can lead to cell death.  Such synthetic 
lethal interactions between two genes usually indicate that they function in the same 
process, or in parallel, partially redundant, processes.  This concept was used in an 
attempt to identify genes required for exocytic transport from the Golgi.  Based on the 
known role of VPS proteins in one branch of the exocytic pathway, a vps1∆ mutation 
combined with a mutation that results in the block of the remaining transport pathway 
should result in synthetic lethality.  However, this strategy was unsuccessful in 
identifying novel components of the exocytic transport machinery, indicating that 
transport routes are more complex than simply two possible pathways.  Therefore, an 
additional mutation, apl2∆, was added to the screen strain background, to screen for 
mutations in a third gene that would result in lethality (27).  
! APL2 encodes β-adaptin, which is a large subunit of the AP-1 clathrin adaptor 
complex.  As mentioned in the previous section, the AP-1 adaptor is thought to 
functions in the sorting of cargo molecules into some classes of clathrin-coated vesicles.  
However, the exact function of AP-1 is unclear, and there is evidence that it functions 
either at the TGN, early endosomes, or both (45: 67).  The apl2∆ mutation was chosen 
because both the vps1 and apl2 mutations perturb the invertase-transporting pathway, 
but they appear to block transport at different steps along this pathway (27).  A screen 
for synthetic lethality in a vps1∆ apl2∆ double-mutant background led to the 
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identification of a novel gene involved in late exocytic transport, AVL9 (27).
! Phenotypic characterization of the avl9∆ mutant indicates that it plays a role in 
transport from the Golgi, most likely in both of the known exocytic pathways (27). 
When Avl9 was depleted in a vps1∆ apl2∆ strain, the cells had an exocytic defect and 
accumulated abundant structures that resemble aberrant Golgi membranes seen in 
mutants that block the exit from the Golgi, such as sec14 and sec7.  The avl9 mutation 
alone or vps1Δ apl2Δ mutations do not generate such phenotypes (27).  Characterization 
of the avl9Δ mutation by itself (so that Vps1 and Apl2 are present) by both subcellular 
fractionation and electron microscopy showed that the mutation perturbs the formation 
of secretory vesicles (27).  In addition, over-expression of Avl9 is highly toxic to 
otherwise wild-type cells and results in the accumulation of heterogeneous membrane 
compartments, as well as a transport defect that appears to be specific for the late 
exocytic pathway (27).  These results indicate that the screen strategy is successful in 
identifying novel components of the late exocytic pathway.  However, the screen, and 
gene cloning, was very laborious due to the requirement of triple-mutant lethality.  My 
thesis work used a very similar rationale as the AVL mutant screen, but rather than 
screening for mutants, my work involved high-throughput screens for small molecules 
that generate the AVL (apl2 vps1 lethal) phenotype.  Targets of some of the small 
molecules that generate the AVL phenotype could be genes that are involved in a 
process related to Avl9 function, or they could target Avl9 itself.  Alternatively, the small 
molecules could target additional novel components of the late transport machinery, or 
regulators of this machinery. 
The TOR Signaling Pathway regulates cell growth
The main goal of my thesis research was to characterize the effects of the compounds 
that we identified in two high-throughput screens for secretory inhibitors (described in 
Chapters 2 and 3).  In addition, I pursued the identification of compound targets, and/
or proteins that are relevant to the functions of the compound targets (described in 
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Chapter 2).  One suppressor that I identified for our best secretory inhibitor was over-
expressed GTR2.  This gene encodes a Ras-type small GTPase, which functions as an 
amino acid-dependent upstream regulator of TORC1 (Target of Rapamycin Complex 1)
(17; 22; 50).  In this final section of my introductory chapter, I will briefly describe the 
TORC1 signaling pathway, with a focus on the upstream regulation of this pathway, 
including regulation by Gtr proteins and their metazoan homologs, the Rag proteins.  In 
Chapter 4, I will speculate more on how the TORC1 signaling pathway and Gtr proteins 
tie in with regulation of transport in the late exocytic pathway. 
There are two complexes that contain TOR: TORC1, which is sensitive to rapamycin, 
and TORC2, which is not, at least in most assays.  The TOR protein in these complexes 
is a highly-conserved Ser/Thr kinase that regulates cell growth and metabolism in 
response to environmental factors (30).  TORC1 is stimulated by nutrients to positively 
regulate cell growth by up-regulating anabolic processes, including translation and 
ribosome biogenesis.  Activation of TORC1 also negatively regulates catabolic processes 
by down-regulating stress-responsive gene transcription and autophagy.  In contrast, 
the mechanisms that regulate TORC2 are less-well understood, and they do not appear 
to be directly connected to nutrient levels (15).
In metazoan cells, TORC1 regulates cell growth by integrating various upstream 
signals, whereas in yeast, nitrogen source level and quality is the primary signal that 
controls TORC1 (reviewed in (70)).  The major inputs that regulate TORC1 signaling in 
metazoan cells are growth factors, nutrients, energy, and stress.  The best-understood 
pathway upstream of TORC1 is the pathway mediated by growth factors.  TOR is 
activated in response to growth factor signals via PI3K-mediated activation of the 
kinase Akt/PKB.  The Akt/PKB kinase inhibits Tsc1/2 (tuberous sclerosis proteins), 
which form a GTPase-activating protein (GAP) complex for the GTPase, Rheb1.  
Inactivation of Tsc1/2 by Akt/PKB leads to the activation of Rheb1, which in turn 
stimulates TOR (70).  Other signals such as stress and energy also regulate Tsc1/2, and 
this is through other kinases: LKB, AMP-activated kinase, and MAPK (Mitogen-
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activated protein kinase).  However, Tsc1/2 is not affected by a major regulator of TOR, 
which is amino acid level (70).  Until recently, TOR regulation by amino acids and other 
nitrogen sources was not understood in either yeast or metazoan cells.  
A clue for amino-acid dependent regulation of TORC1 first came from work by 
Duboluoz et al., in a yeast study aimed at identifying stimulators of TORC1 following 
recovery from starvation (17).  That study identified a complex containing the small 
GTPase, Gtr2, as a key regulator required for amino acid-dependent and TOR-
dependent recovery from starvation.  Gtr2, along with its paralog and binding partner, 
Gtr1, was also identified in a similar complex by a yeast genetic screen aimed at 
identifying nitrogen-source-dependent regulators of amino acid permease transport 
(22).  The strongest evidence for Gtr proteins as amino acid-dependent upstream 
regulators of TORC1 and traffic came from more recent studies in Drosphila (32) and 
mammalian cells (50).  The metazoan orthologs of Gtr1 (RagA/B) and Gtr2 (RabB/C) 
regulate TORC1 activity by regulating its localization to compartments that contain its 
activator, Rheb1; furthermore, this function of Rag proteins is dependent on amino acids 
and is required for the amino acid-dependent regulation of cell growth (32; 50).
My identification of GTR2 as a gene-dosage suppressor of a small-molecule inhibitor 
of the late exocyic pathway further implicates Gtr2 in the regulation of protein traffic.  
Furthermore, based on the known functions of Gtr2, this regulation may involve TOR 
kinase, implicating this kinase in the regulation of cell growth by regulating traffic to 
the cell surface.  These concepts are discussed in more detail in the final chapter of my 
thesis.
Summary
! The discovery that VPS proteins function in one branch of the exocyitc pathway was 
critical in the design of classical genetic (mutant) screens and chemical genetic (small 
molecule) screens aimed at discovering genes and molecular tools that will help us to 
understand the mechanisms of late exocytic transport.  Furthermore, the results of my 
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experimental work, especially the identification of Gtr2 function as a suppressor of the 
inhibiting effects of one of our new compounds, indicate that some of the compounds 
we identified in the chemical genetic screen will serve as tools for understanding the 
signaling pathways that regulate traffic in the late exocytic pathway.
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Chapter 2
A chemical genetic screen for modulators of exocytic transport identifies 
inhibitors of a transport mechanism linked to GTR2 function
Work from this chapter was published in Eukaryotic Cell, Vol. 9, p. 116-126 (2010) and 
reproduced here with permission from the publisher.
Introduction
! Cell growth and proliferation as well as the regulation of cell surface composition 
are achieved by an intracellular transport machinery that delivers proteins and 
membrane to the cell surface.  The transport machinery is regulated by environmental 
sensing and signaling pathways that are integrated for the fine-tuned control of 
transport to the cell surface.  The mechanisms that regulate cell growth and 
proliferation are highly robust; therefore, they can function in a wide range of 
environmental conditions and even when some components of the transport or 
signaling machinery fail.  In eukaryotic cells, this robustness is achieved in part by a 
complex network of membrane and protein traffic routes to the cell surface (17, 33).  
Defects in a transport pathway can result in cargo transport by an alternate route, 
making transport defects difficult to detect in mutant screens (17, 18).  Therefore, 
relatively little is known about the mechanisms by which protein and membrane cargo 
is transported from late exocytic sorting compartments, the Golgi and endosomes, and 
we have yet to identify most of the components that mediate and regulate this process.
! Complex processes are more readily understood in relatively simple organisms.  
For this reason, the budding yeast Saccharomyces cerevisiae has become one of the most 
powerful experimental models for understanding intracellular transport, and most of 
the conserved components of the exocytic traffic machinery were first discovered using 
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yeast genetic strategies (27).  We used a yeast genetic screen to identify a novel 
component of the late exocytic transport machinery, Avl9, a member of an ancient 
eukaryotic protein superfamily (18).  Avl9 is essential in a mutant strain lacking Vps1, a 
dynamin homolog that functions in transport vesicle formation at a late Golgi 
compartment (26, 34), and also lacking Apl2, a large subunit of the adaptor protein-1 
(AP-1) complex, which is required for forming certain classes of clathrin-coated vesicles 
at the Golgi and endosomes (18, 19, 31, 42).  The apl2∆ and vps1∆ mutants have defects 
in an exocytic pathway(s), but these mutants, as well as an apl2∆ vps1∆ double-mutant, 
grow well because cargo is rerouted into a remaining pathway(s) (18).  Mutations such 
as avl9∆, which are lethal in a apl2∆ vps1∆ strain but not in a wild-type strain, are 
expected to cause defects in a branch of the exocytic pathway that remains functional in 
the apl2∆ vps1∆ strain.  Analogous to using mutagenesis to screen for a secretory block 
in the apl2∆ vps1∆ mutant, we performed a high-throughput screen of a large library of 
small molecules to identify compounds that inhibit the growth of the vps1∆ apl2∆ 
mutant but which have relatively little effect on wild-type cells.  The targets of these 
compounds are potential components of the secretory machinery, and some of the 
compounds may interfere with an Avl9-related function.  The biochemical function of 
Avl9 and related proteins is still unknown, and the inhibitors identified by our screen 
strategy could be valuable tools in understanding the role of Avl9 in both yeast and 
mammalian cells.  
! Our high-throughput screen was successful in identifying novel exocytic transport 
inhibitors, and we describe the phenotypic effects of one structurally similar group of 
compounds in detail.  Furthermore, we show that the toxic effects of this group of 
compounds is inhibited by highly expressing GTR2, which encodes a Ras-like small 
GTPase that plays a role in regulating nutrient-responsive TORC1 (Target Of 
Rapamycin Complex 1) kinase signaling, exocytic cargo sorting at endosomes, and 
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epigenetic control of gene expression (7, 11, 14, 25, 37).  Therefore, the small molecules 
identified by our chemical-genetic approach are promising tools for understanding how 
signaling pathways that respond to environmental conditions regulate the traffic 
pathways that mediate cell growth and proliferation. 
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Materials and Methods
Reagents, plasmids, and yeast strains
! Minimal medium for growing plasmid-carrying yeast strains was CSM (complete 
synthetic medium) lacking a nutrient for plasmid selection, with amino acid mixes from 
Q-Biogene.  All other growth media components were from Difco, and were prepared 
following recipes described in (39).  Rich medium was YPD (yeast extract, peptone, 2% 
glucose) or YPGal (yeast extract, peptone, 2% galactose) unless otherwise stated.  
Culture growth was monitored by measuring OD600 in a Genesys 5 spectrophotometer 
(Thermo-Fisher).  Rapamycin was from Sigma-Aldrich and prepared as described in (6).  
Hit compounds from high-throughput screening were reordered from ChemBridge 
(KU#1-11) or ChemDiv (KU#12-15). 
! Our “wild-type” yeast strains are EHY46 and EHY47 (18).  EHY361 is a vps1∆ 
mutant strain in the EHY47 background (18).  EHY644 is an apl2∆ vps1∆ mutant strain 
(obtained from EHY361 crossed to GPY1783-10A; (18)).  EHY644 was transformed with 
pEH227, which is pRS316 with VPS1 (18) to generate EHY658; with pEH331, which is 
pRS316 with APL2 (18) to generate EHY1166; or with an “empty” vector, pRS316, which 
is a URA3 CEN plasmid (40) to generate EHY707.  EHY807 is an apl2∆ strain, generated 
from EHY47 by integrating a PCR product containing apl2∆::kanMX4 (obtained from 
Y12725 using primers EH130, EH131; (18)).  EHY1325 is a wild-type diploid generated 
by crossing EHY47 to EHY46.  GTR2 was deleted in this diploid to generate EHY1326 
by integrating a PCR fragment containing gtr2∆::LEU2 (using primers EH212: 
GGAAAGGACCGTTTCCGGAC and EH213: CGACCCCCATCGTGAGTGCT), 
obtained from strain NBW5∆gtr2 (a kind gift of Takeshi Sekiguchi; (25)).  EHY1326 was 
sporulated, and gtr2∆ progeny (LZY260) was crossed to EHY644 to obtain the following 
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haploid progeny: gtr2∆ vps1∆ apl2∆ (LZY253); gtr2∆ apl2∆ (LZY256); and gtr2∆ vps1∆ 
(LZY257).  
! Plasmids containing mutant alleles of GTR1 and GTR2 that encode proteins 
restricted to the GDP- or GTP-bound conformations were the generous gift of Takeshi 
Sekiguchi (Kyushu University), and are pL146, pL148, pL264, and pL263 (described in 
(25, 43).  We switched the TRP1 auxotrophic marker in these plasmids to URA3 for use 
in our strains, using the pTU marker-swapper plasmid (9).  Plasmid pLZ43 contains 
GTR2 (20 upstream and 61 downstream bp) under the control of the GAL1 promoter, 
and was isolated from a cDNA library (22).  Plasmid pLZ44 contains GTR1 under the 
control of the GAL1 promoter and was generated by cloning a genomic PCR fragment 
(using primers LZP48: GTAATGTCGTCAAATAATAGGA and LZP26: 
AAACACTCAATTGCCGAATGT) into pCR-BluntII-TOPO, using the Zero-Blunt TOPO 
kit (Invitrogen).  The GTR1-containing insert was then subcloned into pRS316-GAL (22) 
using the PstI and SacI restriction enzyme sites.
High-throughput screen
! Our high-throughput screen for compounds that selectively inhibit the growth of 
an apl2∆ vps1∆ yeast strain was performed at the University of Kansas High 
Throughput Screening Laboratory, which has a collection of over 100,000 compounds 
selected from the ChemBridge, ChemDiv, and Prestwick Libraries.  101,376 screening 
compounds were distributed in 384-well plates.  Each plate had 352 wells for 
compounds and 32 wells for positive control (no cells) and negative control (DMSO 
without screening compound).  The plates were seeded with an overnight (18-hour) 
culture of EHY644 (apl2∆ vps1∆)grown at 24°C in YPD to OD600 0.05 (early log phase).  
80 µl of culture was mixed with 20 µl of compound dissolved in 2.5% DMSO, for a final 
concentration of 5 µg/ml compound, 0.5% DMSO, in 100 µl per well.  The plates were 
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then stacked (but not sealed) and incubated at room temperature for 15-17 h to a final 
average OD600 of 0.8 (close to late exponential growth under these conditions).  Plates 
were read on an Envision multilabel plate reader (PerkinElmer, Wellesley, MA).  We 
defined hits as those compounds that gave an OD600 that was 60% lower than that of 
the negative control.  We identified 279 hits from screening with the apl2∆ vps1∆ mutant. 
These hits were then tested with both the apl2∆ vps1∆ mutant (EHY644) and the 
corresponding wild-type strain (EHY47), in a 6-point dose-response assay (0.15 µg/ml - 
5 µg/ml) in 96-well plates.  Of the 279 primary screen hits, 15 compounds inhibited the 
growth of the apl2∆ vps1∆ mutant strain but were significantly less toxic to the wild-type 
strain.  
Assays for drug effects
! All liquid cultures for growth assays and secretion assays were grown at 24°C, with 
the exception of the pulse-chase assays, which were performed at 30°C.  (Growth at 
24°C and 30°C was compared for the enzymatic invertase assay in selected samples, and 
no difference in results was observed for the two temperatures.)  Yeast on agar plates 
were incubated at 30°C.  For shaking-culture exponential-phase growth assays, cells 
were grown overnight to early exponential phase in CSM (minus uracil) medium to 
maintain plasmids.  They were then diluted to OD600 0.07, and compounds dissolved 
in DMSO were added at the indicated concentrations, with final DMSO concentration of 
0.25% in each case.  Cultures were placed on a rotating platform for aeration, and 
OD600 readings were taken every 2 hours at least five times to generate an exponential 
growth curve.  Rates were calculated from an exponential curve fit equation using 
Kaleidagraph 3.6 (Synergy Software; Reading, PA).  The correlation coefficient 
(Pearson's R) was >0.9 in each case.  
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! The invertase, Bgl2, and CPY transport assays were performed as described 
previously (18).  For the invertase assay, we grew cells overnight to exponential phase in 
either YPD or CSM (to select for CEN plasmids), then shifted them to fresh YPD with 
5% glucose for 2-3 hours.  Compound or DMSO control was then added to this medium 
at the indicated concentration and cultures were grown for an additional 15 min, 
followed by shifting cells to YPD with 0.1% glucose (to derepress invertase expression) 
plus compound or DMSO control for 90 min prior to performing the invertase secretion 
assay as described previously (18).  Results from at least three independent cultures 
grown on different days were averaged, and variability is indicated as SEM (standard 
error of the mean).  Statistical significance (using a student t-test) was calculated using 
Kaleidagraph 3.6 software.  Pulse-chase analysis of transport kinetics was performed as 
in (18).  Briefly, exponential-phase cells were inoculated into CSM, -Cys, -Met at 4 
OD600/ml, shaken at 30°C for 5 min, and compound or DMSO control was added for 
20 min prior to a 4-min pulse with 25 µCi labeling mix/OD600 cells.  Chase for 2-20 min 
was with excess cold amino acids, and cells were processed for immunoprecipitation 
and detection of Bgl2, invertase and CPY as described (18).  Cells for thin-section 
electron microscopy were grown at 30°C in YPD, and prepared as described previously 
(18).
Screen for gene overexpression suppressors of drug effects
! To screen for genes that, when overexpressed, can suppress the toxic effects of our 
drugs, we used both a 2µ (high copy) genomic library (5) and a GAL-promoter-driven 
cDNA library (22).  Only the cDNA library yielded a suppressor clone.  For that library, 
we screened for suppressors in strain EHY644 (apl2∆ vps1∆).  The strain was 
transformed with library DNA using the method of Schiestl and Gietz (36), and cells 
were plated on CSM -Ura, 2% galactose plates with compound (1 µM KU#7 or 2 µM 
KU#4).  Plasmids were recovered from colonies that could grow on drug plates and re-
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transformed and re-tested for suppression in EHY644.  Plasmids that retested were 
sequenced at the insert junctions to identify the suppressing gene. 
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Results
A high-throughput screen for compounds that are selectively toxic to a vps1∆ apl2∆ 
mutant strain
! We performed a high-throughput screen of a library of drug-like molecules for 
compounds that inhibit the growth of a yeast strain with apl2∆ and vps1∆ mutations but 
which have relatively small effects on a corresponding background strain.  Our goal 
was to identify compounds that generate an AVL phenotype (apl2 vps1 lethal), 
analogous to the phenotype of an avl9∆ mutant (18).  Of 101,376 compounds screened, 
279 significantly inhibited the growth of a vps1∆ apl2∆ mutant (less than 40% of growth 
without drug).  These compounds were then screened in dose-response growth assays 
to eliminate compounds that inhibited the growth of both wild-type and mutant strains. 
Of our 279 initial hits that inhibited the growth of a vps1∆ apl2∆ mutant, we identified 15 
hit compounds that selectively inhibited the growth of the mutant strain. 
! Seven of the 15 hit compounds could be grouped into two groups based on similar 
structures, whereas the rest of the structures were unique (Figure 1).  We identified four 
similar compounds that we named Group A, and three compounds that we named 
Group B.  A fifth Group A compound, KU#7f, was not identified in our screen but was 
purchased as a substitute for KU#7 when that compound was no longer available from 
the supplier (KU#7f is somewhat more active than KU#7 in our assays).  Dose-response 
growth assays in 96-well plates for representative Group A compounds and a Group B 
compound are shown in Figure 2a.  Piperazine rings are common in drug-like 
molecules, but the published bioactive piperazine derivatives that most resembled our 
Group A structures (12, 44) did not have growth-inhibiting activity for our mutant 
strains, when tested at up to 10 µM.  In particular, we found that the N-benzoyl 
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Figure 1.  Structures of all 15 hit compounds identified in a high-throughput phenotypic 
screen of a 101,376-compound library for small molecules that have an AVL (apl2∆ vps1∆ 
lethal) effect.  Some of the confirmed hit compounds grouped into two structural 
groups, Group A and Group B, whereas other hits had unique structures (“sinlgetons”).
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substituent was essential for the activity of our Group A compounds, because similar 
piperazine compounds that did not have this substituent (12) had no effect in our assays 
(our unpublished observations).  We did not find published examples of bioactive 
compounds that resembled our Group B compounds.
Group A compounds selectively inhibit the growth of apl2∆ and vps1∆ mutants
! We tested all of our 15 hit compounds in exponentially growing shaking cultures 
for growth-inhibiting activity and found that the Group A compounds had the most 
rapid (within 30 min), dramatic effect on the growth of either the apl2∆ or vps1∆ or apl2∆ 
vps1∆ mutant strains, with relatively much smaller effect on the growth of our wild-type 
strain (Figure 2b).  However, when grown on solid medium, the toxic effects of the 
compounds were specific to the apl2∆ vps1∆ strain; thus, the Group A compounds have 
an AVL (apl2∆ vps1∆ lethal) effect (Figure 2c).  It is possible that rapidly-growing cells in 
shaking cultures, in which membrane trafficking occurs at a greater speed than it does 
in cells grown on plates, are more sensitive to Group A compounds.  Alternatively, our 
results could reflect the time scale of the assays, a few hours in shaking cultures at 
exponential growth, compared to several days on plates, in which time the vps1∆ and 
apl2∆ single-mutants could possibly adapt to the effects of the compounds. 
! In contrast to Group A compounds, most of our hit compounds initially did not 
appear to inhibit growth of exponentially growing shaking cultures.  This included the 
Group B compounds, which consistently strongly inhibited the growth of the apl2∆ 
vps1∆ strain but not the wild-type strain when the growth assay was performed in 96-
well (non-shaking) liquid cultures (Figure 2a) or agar plates (not shown).  However, we 
found that after growing cells for a longer time (>4 hours), growth inhibition in shaking 
liquid cultures became apparent in Group B compounds (results not shown).  The delay 
in growth defect was not due to a need for build-up of compound in cells, because we 
33
Figure 2 (following page).  Group A and Group B compounds have mutant-specific 
effects on growth.  (A) Dose-response growth assays for KU#6 (Group A), KU#7 (Group 
A) and KU#10 (Group B) compounds.  Wild-type and apl2∆ vps1∆ (“mutant”) cells were 
grown in the presence of compound or DMSO control in 96-well plates.  Compounds 
were at the following concentrations, prepared by 2-fold serial dilutions:  5, 2.5, 1.25, 
0.625, 0.31, and 0.15 µg/ml.  The graphs show [(OD600 in compound)/OD600 in 
DMSO]x100, after ~18 h growth.  (B) Growth rates of exponential-phase cells in shaking 
cultures.  Overnight exponential-phase cultures were diluted to OD600 0.07, and 
compounds or DMSO control were added at the indicated concentrations with final 
DMSO concentration of 0.25% in each case.  Cultures were grown with aeration, and 
OD600 measurements were taken over ~9h of growth to generate growth curves.  Rates 
were determined from an exponential curve fit equation (correlation coefficients >0.9 in 
each case).  (C) Growth on solid media in presence of Group A compounds.  Cultures 
were grown to OD600 1.0 and spotted on a YPD plate containing 1 µM KU#7f and on a 
control plate, after 4-fold serial dilutions.  Mutant strains have an EHY47 wild-type 
background and are identical except for the plasmids they contain:  EHY658 (apl2∆), 
EHY1166 (vps1∆), and EH707 (apl2∆ vps1∆).
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noticed the same time delay in lower and higher concentrations of the drug.  It is 
possible that these compounds affect gene expression or signaling pathways that 
regulate growth. 
Group A compounds inhibit exocytic transport
! It is difficult to interpret results with slow-acting growth inhibitors, so we focused 
on analyzing the effects of Group A compounds, which rapidly inhibited the growth of 
our mutant strains.  To determine whether the toxicity of these compounds is due to a 
transport block, we assayed the effects of the compounds on exocytic cargo transport.  
In wild-type yeast, two pathways can transport exocytic cargo.  One route transports 
the cell wall protein Bgl2, whereas another route transports the periplasmic enzyme 
invertase (16).  These two cargoes are sorted into one pathway in a vps1∆ mutant, in 
which the normal invertase pathway appears to be blocked (17).  Bgl2 transport can be 
conveniently assayed, because at steady state most of this protein is in the cell wall, 
which can be removed by enzymatic digestion (spheroplasting).  Wild-type cells have 
very little Bgl2 after spheroplasting, which represents intracellular Bgl2 in transit to the 
cell surface.  We found that 15 min after adding compound, intracellular accumulation 
of Bgl2 was detected in the vps1∆ and apl2∆ mutants but not in the corresponding wild-
type strain (Figure 3).  This accumulation was very dramatic after 90 min, indicating a 
significant defect in Bgl2 transport.
! We also assayed the transport of a periplasmic enzyme, invertase, in the presence of 
Group A compounds.  Invertase expression is repressed when cells are grown in 2% 
glucose, and expression is derepressed when cells are shifted to 0.1% glucose (8).  There 
is no detectable invertase secretion prior to derepressing expression.  We added 
compounds to cells 15 min prior to derepression, and then shifted cells into low glucose 
with compound for 90 min, followed by enzymatic assays for invertase secretion 
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Figure 3.  Group A compounds cause internal accumulation of the cell wall protein, 
Bgl2, in apl2∆ and vps1∆ mutant strains.  Cells were grown to exponential phase, and 
compound KU#4 (Group A) was added at 10 µM for the indicated times.  DMSO 
controls (“D”) represent 60-min time-point samples.  The cell walls were digested to 
remove external Bgl2, and internal Bgl2 was assayed by western blotting.  Actin is 
shown as loading control.  Strains are as in Figure 2.
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Figure 4.  Group A compounds cause a mutant-specific defect in invertase secretion.  
Cultures were grown to exponential-phase in high-glucose medium, and compound 
was added for 15 min before shifting to low glucose with compound (to derepress 
invertase expression).  Growth in compound was continued for 90 min.  External 
invertase was compared to total invertase by an enzymatic assay to calculate the percent 
of invertase secreted.  Strains are as in Figure 2.  The means of three experiments (from 
three independent cultures) are shown.  Error bars, SEM.
38
0
20
40
60
80
wt
DMSO
KU#7 0.5 µM
KU#7 1 µM
KU#7 2.5 µM
%
 In
ve
rta
se
 S
ec
re
te
d
wt
KU#6 1 µM
KU#6 2.5 µM
KU#3 5 µM
KU#3 10 µM
KU#4 2.5 µM
KU#4 5 µM
%
 In
ve
rta
se
 S
ec
re
te
d
0
20
40
60
80
Figure 4
(Figure 4).  We observed a very significant secretory defect for the apl2∆ mutant in as 
low as 0.5 µM compound KU#7, the lowest concentration that we assayed.  We found 
similar effects on secretion for all of our Group A compounds, and the apl2∆ mutant was 
consistently the most sensitive to compound in this assay (Figure 4).  The mutant strains 
were identical except for the plasmids that they contained (double mutant with either 
empty vector, or vector with VPS1 or APL2).  It is possible that the double mutant 
adapts to the transport defect in some way that makes it less sensitive to compound in 
this assay.  Interestingly, the relative invertase secretion defects in the different mutants 
did not correspond with the relative growth decrease in compounds (Figure 2b,c).  
! ! The secretory assays described above have the advantage of being very sensitive for 
detecting transport defects.  However, the assays show cargo accumulation over time, 
rather than an immediate effect on transport kinetics.  Therefore, we also performed 
metabolic labeling and pulse-chase analysis of secretory cargo to determine whether the 
compounds had observable effects on transport kinetics in this assay (Figure 5).  In the 
absence of inhibitors, about half of the Bgl2 is exported within 5 min, while transport of 
invertase is faster (Figure 5 a,c shows results for apl2∆; results are similar for wild type).  
Both wild-type and apl2∆ cells show a defect in Bgl2 transport kinetics in compound 
KU#4 and KU#7 (Figure 5b), and the defect is more substantial in apl2∆ cells.  The 
slower transport kinetics was most easily observed at early chase time points, but there 
was not a complete transport block, and most Bgl2 was secreted by 20 min (not shown).  
KU#4 and KU#7 also slowed invertase transport in the apl2∆ mutant, but not in wild-
type cells (Figure 5d).  However, invertase transport is normally very fast, so it is 
difficult to detect a partial transport block by pulse-chase analysis.  Wild-type cells did 
show a defect in the enzymatic invertase secretion assay (Figure 4), but internal 
invertase in that assay represents accumulation over 90 min.  Furthermore, the 
enzymatic assays also show an incomplete transport block for wild-type and even 
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Figure 5.  Pulse-chase analysis shows a kinetic lag of Bgl2 and invertase exocytic 
transport in the presence of Group A compounds.  Cells were pre-incubated with 
compound or DMSO control for 20 min and metabolically labeled with 35S cysteine and 
methionine for 4 min, followed by addition of excess unlabeled amino acids for 2-20 
min chase times (A, C, E) or for a 5 min chase (B and D).  The inside (I) fraction was 
separated from the cell wall and media fraction (O), and Bgl2 (A, B), invertase (C, D) 
and CPY (E) were immunoprecipitated and detected by phosphorimaging.  Bgl2 is not 
visibly modified, whereas invertase has an ER form and a Golgi-modified (G) 
heterogeneously glycosylated form.  CPY has a 67 kDa ER form, a 69 kDa Golgi form, 
and a 61 kDa vacuole form.  Group A compounds do not cause a defect in ER-to-Golgi 
or Golgi-to-vacuole transport of CPY.
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Figure 6.  Group A compounds cause accumulation of Golgi or endosome-like 
membranes.  An apl2∆ strain (EHY807; A, B) or wild-type (EHY47; E) were grown in the 
presence of 2.5 µM compound KU#7 for 30 min.  Similar results were obtained for apl2∆ 
cells grown in 10 µM KU#3 (a less-potent Group A compound) for 60 min (C).  DMSO 
controls without compound are shown in D (apl2∆) and F (wild type).  Cells were 
prepared for thin-section electron microscopy as described (18).  The scale bars 
represent 200 nm (A), or 500 nm (B-F).
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mutants, at the drug concentrations we tested (for comparison, the sec6-4 conditional 
secretory mutant secretes <5% invertase at restrictive temperature in this enzymatic 
assay; (27) and our unpublished observations).  The transport defects caused by our 
compounds appear to be specific to the late exocytic pathway, because pulse-chase 
analysis of transport of a vacuolar protein, CPY, showed no detectable defect in ER-to-
Golgi transport or transport from the Golgi to vacuole (Figure 5e).
Group A compounds cause accumulation of Golgi-like membranes
! To further define the membrane traffic defects caused by our Group A compounds, 
we examined the ultrastructure of cells grown in the presence of KU#7 or KU#3 by thin-
section electron microscopy (Figure 6).  The apl2∆ strain showed dramatic accumulation 
of membranes when grown in KU#7 for just 30 min (Figure 6a, b).  Most of the 
membranes were clusters of vesicles and/or tubules (tubules and fenestrated 
membranes could appear as clustered vesicles in the plane of a thin section).  Another 
common and striking structure was a ring of discontinuous membranes (enlarged inset 
in Figure 6a; also seen in Figure 6b,c,e).  Similar rings were observed in cells grown in 
the presence of KU#3 for 60 min (Figure 6c; KU#3 is our least-effective Group A 
compound).  Because the rings were consistently circular, they likely represent 
fenestrated spheres, structures also observed in sec14-ts mutants after a short shift to a 
restrictive temperature (32) and in an arf1∆ mutant (15).  Gaynor et al. (15) observed 
both very large and smaller rings in arf1∆ cells, and from complementing 
immunolocalization studies by light microscopy, they concluded that the large rings 
likely represent aberrant endosomes, whereas the smaller rings represent Golgi 
membranes.  In our samples, we did not observe the very large rings seen in the arf1∆ 
mutant.  However, the arf1∆ and sec14-ts mutants have defects in transport from both 
Golgi and endosomes (15, 23), and the invertase-transporting exocytic pathway likely 
transits endosomes (17), so our Group A compounds could perturb exit from either or 
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both the Golgi and endosomes.  Wild-type cells had a similar but less abundant 
membrane-accumulation phenotype when grown in the presence of KU#7 (Figure 6e).  
We did not observe these abnormal membranes in either apl2∆ cells or wild-type cells 
grown in DMSO control (Figure 6d, f), although the apl2∆ cells had occasional small 
continuous rings which represent cup-shaped structures, similar to but much smaller 
than Berkeley bodies, thought to represent aberrant Golgi, in sec7-ts and sec14-ts 
mutants (27)).  We also observed small continuous rings in cells grown in KU#7, but 
these were likewise smaller and rarer than the structures accumulated by sec7 and sec14 
mutants.  Cells grown in KU#7 for 1h had a similar phenotype (not shown), so the 
fenestrated spheres did not progress to Berkeley bodies at the drug concentrations we 
tested.  It is possible that the fenestrated spheres and tubules represent an incomplete 
block in exit from the Golgi (as is the case with the arf1∆ mutant described in (15)).  
Alternatively, the different abnormal membranes may represent different molecular 
defects.  
Toxicity of Group A compounds can be suppressed by overexpressed GTR2
! A relatively simple strategy for identifying potential drug targets, or genes that are 
relevant for the function of a drug target, is a screen for gene-dosage suppression of the 
drug effects.  We screened both a 2µ (multicopy) genomic library and a GAL-promoter-
driven cDNA library (22) for genes that, when overexpressed, can suppress the toxicity 
of Group A compounds.  We obtained no suppressors from the 2µ library and only one 
strong suppressor gene from the cDNA library.  We identified the suppressor gene as 
GTR2 (Figure 7).  Gtr1 and Gtr2 are homologous Ras-like GTP binding proteins that 
form hetero- and homo-dimers (14, 25).  They function as nutrient-responsive regulators 
of the TORC1 signaling pathway (7, 11), exocytic sorting of the Gap1 general amino acid 
permease at endosomes (14), and epigenetic control of gene expression (37).  Although 
Gtr1 and Gtr2 are thought to function as obligate heterodimers, Gtr1 had no 
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suppressing effect when highly expressed from the GAL promoter (Figure 7).  A 2µ 
(high-copy) plasmid containing GTR2 under its native promoter could not suppress 
toxicity either on glucose or galactose (our unpublished observations).
A dominant-negative form of the Gtr complex and decreased TORC1 signaling suppress 
the secretory defect caused by Group A compounds
! Our invertase secretion assay is not compatible with growth on galactose-
containing media, so we could not use our GAL-GTR2 construct to test whether 
overexpression of GTR2 can suppress the effects of Group A compounds on invertase 
secretion.  Instead, we used mutant alleles of the GTR genes expressed from their native 
promoters in CEN (low-copy) plasmids.  The Gtr1/Gtr2 dimer, as well as the metazoan 
counterpart, RagAB/RagCD, are active in positively regulating TORC1 signaling when 
Gtr1 (or RagA or RagB) is GTP-bound and Gtr2 (or RagC or RagD) is GDP-bound.  
Furthermore, in the opposite conformations (Gtr1/RagAB in a GDP-bound state and 
Gtr2/RagCD in a GTP-bound state) have a dominant-negative effect on TORC signaling 
(7, 11, 20, 35).  Likewise, the Gap1 permease is sorted from a vacuolar pathway to the 
exocytic pathway when Gtr1 is GTP-bound and Gtr2 is GDP-bound, but not when the 
GTPases are restricted to the opposite conformations (14).  We tested GTR alleles that 
express either GTP-restricted or GDP-restricted forms of the proteins for effect on 
invertase secretion in apl2∆ vps1∆ cells grown in presence of KU#7f (Figure 8a).  We 
found that both Gtr1 and Gtr2 can partially suppress the effects of KU#7f on secretion, 
and only when the GTPases are restricted to the conformations that are expected to 
form a dominant negative complex.  Although the suppression of the secretory defect 
was not dramatic, the Gtr proteins were not overexpressed in these experiments, and 
the wild-type proteins were also present.  Furthermore, the results were consistent in 
each repeat of the experiment and statistically significant (P = 0.001 for secretion with 
empty vector compared with secretion when Gtr2-GTP is expressed).  In contrast, the 
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Figure 7.  Overexpression of GTR2 on galactose-containing medium suppresses the 
toxic effect of Group A compounds.  The strains are described in Materials and Methods 
and are as follows: EHY47 with pRS316, EHY807 with pLZ43; EHY807 with pRS316, 
EHY361 with pLZ43, EHY361 with pRS316, EHY644 with pLZ43, EHY644 with pLZ44, 
and EHY644 with pRS316.
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Figure 8.  Dominant-negative Gtr proteins and sub-inhibitory rapamycin suppress the 
invertase secretion defect caused by Group A compounds.  (A) An apl2∆ vps1∆ mutant 
strain (EHY644) was transformed with empty vector (pRS316) or pRS-based (CEN) 
vectors expressing GDP- or GTP-restricted mutant forms of Gtr1 and Gtr2, from their 
native promoters.  The strains were tested for invertase secretion after growth in 0.5 µM 
KU#7f, as described for Figure 4.  For each strain, the means were calculated from 7 
repeats (for KU#7f) or 3 repeats (for DMSO).  Each repeat was an independent culture.  
(B) An apl2∆ vps1∆ mutant strain (EHY644) culture was divided into four samples, 
which were treated with either DMSO (control), or 0.5 µM KU#7f, or 10 ng/ml 
rapamycin, or 0.5 µM KU7f plus 10 ng/ml rapamycin together.  The means from three 
independent (pre-drug) cultures are shown.  (C)  Total invertase activity (secreted plus 
internal) from the cultures used in (B).  Invertase is expressed as A540 units per OD600 
cells from the invertase enzymatic assay.  Error bars, SEM.
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alleles that are expected to form the TORC1-activating form of the Gtr complex (Gtr2-
GDP and Gtr1-GTP) had less or no effect on invertase secretion (Figure 8a).
! Because the “active” Gtr complex positively regulates TORC1 signaling, whereas 
the “inactive” complex has a dominant negative effect on TORC1 activity, we asked 
whether decreasing TORC1 activity also suppresses the secretory defect in the presence 
of KU#7f.  We found that 10 ng/ml rapamycin (which is the amount typically used as a 
sub-inhibitory level, while 200 ng/ml is used to inhibit TORC1; (6)) suppressed the 
secretory defect caused by KU#7f to an extent similar to that of the dominant-negative 
Gtr proteins (Figure 8b).  A nearly identical result was obtained with 20 ng/ml 
rapamycin (not shown), so our results with both the Gtr proteins and rapamycin may 
represent the maximum possible suppression.  Rapamycin alone, either 10 ng/ml (or 20 
ng/ml, not shown) had no effect on invertase secretion in the apl2∆ vps1∆ strain when 
no Group A compound was present (Figure 8b). 
! TORC1 positively regulates translation (45), so we speculated that suppression by 
reducing TORC1 activity may be due to a decrease in cargo flow through the secretory 
pathway, such that the reduced secretory competence due to effects of our Group A 
compound is less deleterious to the apl2∆ vps1∆ mutant.  Cells are grown in the drugs 
for 15 min prior to derepression of invertase expression, followed by 90 min more in 
drug, so some reduction in protein synthesis might eventually occur in the time course 
of our experiments.  However, for the identical samples shown in Figure 8b, we found 
that total invertase (secreted plus internal) was essentially the same when just KU#7f 
was added to cells and when both KU#7f and rapamycin were added (although total 
invertase level was somewhat lower compared to DMSO control, whether or not 
rapamycin and KU#7f were combined or each was present alone).  These results 
suggest that TORC1 activity may regulate membrane traffic in a way that is deleterious 
47
when traffic is perturbed in the apl2∆ vps1∆ mutant by Group A compounds.  We were 
unable to detect suppression of the growth-inhibitory effect of Group A compounds, by 
either the mutant alleles of Gtr proteins or by sub-inhibitory levels of rapamycin.  This 
could be because the invertase assay measures a relatively short-term effect, and the 
long-term effect on growth is not as readily suppressed. 
GTR2 is not a likely direct target of Group A compounds
! Suppression by overexpressed Gtr2 could indicate either that Gtr2 is a target of our 
Group A compounds, or that the function of the drug target is relevant for Gtr2 activity.  
Because Group A compounds are toxic to an apl2∆ vps1∆ mutant, a defect in the drug 
target could likewise be deleterious to the apl2∆ vps1∆ strain.  We found that crossing a 
gtr2∆ mutation into our apl2∆ vps1∆ strain did not noticeably reduce the growth of the 
gtr2∆ apl2∆ vps1∆ triple-mutant progeny (Figure 9).  It is still possible that Group A 
compounds have a dominant effect on Gtr2, or target a regulator of its activity.  
However, this is unlikely, because in such a case, the deleterious effects of the 
compounds would require the presence of GTR2, and we found that KU#7f is at least as 
toxic to a gtr2∆ apl2∆ vps1∆ mutant as it is to an apl2∆ vps1∆ mutant (Figure 9).  
Although we have not yet identified the molecular target of our comounds, we can 
conclude that modulation of TORC1 activity is critical when the effects of Group A 
compounds are combined with the apl2∆ and vps1∆ mutations, and our results are 
valuable in suggesting additional target candidates. 
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Figure 9.  Gtr2 is not a likely target of our Group A compounds.  A gtr2∆ mutation (in 
EHY47 background) was crossed into an apl2∆ vps1∆ strain (EHY644).  All double- and 
triple-mutant progeny were viable; therefore, unlike Group A compounds, gtr2∆ does 
not produce an AVL phenotype.  The gtr2∆ apl2∆ vps1∆ strain was at least as sensitive to 
1 µM KU#7f as was an apl2∆ vps1∆ strain, indicating that the drug does not interact with 
Gtr2 for a dominant effect.  These results show that Group A compounds do not have a 
direct effect on Gtr2 function.
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Discussion
! We screened a 101,376-compound library for small molecules that perturb the late 
exocytic pathway, with the goal of identifying novel molecular probes to help us 
understand the mechanisms and regulation of late exocytic transport.  We identified 15 
compounds that had selective toxicity towards a yeast mutant, apl2∆ vps1∆, in which 
exocytic cargo is rerouted from a defective pathway to an alternative exocytic route.  
Thus, the compounds are expected to perturb a remaining exocytic pathway in this 
mutant, and cause an AVL (apl2 vps1 lethal) phenotype, analogous to the phenotype of 
the avl9∆ mutant identified in a classical yeast mutant screen (18).  Some of our hits fell 
into two groups of similar structures, and one of these groups, which we named Group 
A, was characterized in detail for effects on membrane trafficking.   
! The Group A compounds inhibit the growth of the apl2∆ vps1∆ strain at a low (<1 
µM) concentration, and cause an exocytic defect at <0.5 µM both in this double-mutant 
and the apl2∆ and vps1∆ single-mutants.  The transport defect appears to be specific to 
the late exocytic pathway, because the compounds have no detectable effect on 
transport to the vacuole/lysosme in either apl2∆ or wild-type cells.  Furthermore, the 
compounds cause rapid (within 30 min) accumulation of membranes that resemble the 
aberrant membranes in other mutants with exocytic blocks at the Golgi.  With higher 
concentrations of compound (>2 µM), we detected secretory defects and membrane 
accumulation in wild-type cells as well.  These results indicate that our compounds 
inhibit exocytic transport from the Golgi and possibly endosomes, and thus target a 
molecule or molecules that mediate traffic at these steps.
! We initiated efforts to identify the molecular target of our Group A compounds by 
screening for genes that suppress the toxicity of the compounds when overexpressed.  
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Although Avl9 is a potential target, it is highly toxic when overexpressed (18), and other 
strategies are needed to explore it as a potential drug target.  Our suppressor screen 
identified just one gene, GTR2, which suppressed the toxic effects of our most potent 
Group A compound, KU7f, when highly expressed from the GAL promoter.  Gtr2 and 
its homolog, Gtr1, function as a dimer to regulate numerous nutrient-responsive 
processes, but the primary function of these GTPases and the corresponding metazoan 
proteins is thought to be the regulation of TORC1 signaling, and thus regulation of 
growth (7, 11, 20, 35).  Overexpression of GTR1 could not suppress the toxicity of KU7f, 
a result that was explained in our subsequent assays with GDP- and GTP-restricted 
mutant alleles of the GTPases.  We found that the dominant-negative alleles of the 
GTPases, having a GDP-restricted conformation for Gtr1 and GTP-restricted 
conformation for Gtr2, partially suppressed the invertase secretion defect caused by 
KU7f in the apl2∆ vps1∆ mutant.  Therefore, the overexpressed wild-type proteins are 
likely more abundant in a GTP-bound conformation.  
! The alleles of the GTPases that best suppressed the secretory defect caused by KU7f 
are dominant-negative regulators of TORC1 signaling, and, correspondingly, sub-lethal 
concentrations of rapamycin, a TORC1 inhibitor, likewise suppressed the invertase 
secretory defect caused by KU7f.  This result was not due to a reduction in invertase 
production.  Therefore, TORC1 signaling may regulate a pathway that needs 
modulation in response to secretory transport blocks.  Invertase in wild-type cells likely 
transits endosomes en route to the cell surface (17), and endosomes are the most likely 
site where the Gtr/Rag complex functions in regulating transport in response to amino 
acid signals in both yeast and mammalian cells (14, 35).  Furthermore, TORC1-mediated 
signaling functions at endosomes or the Golgi for sorting the high-affinity tryptophan 
and histidine permeases, Tat2 and Hip1, from an endosome-mediated vacuolar 
pathway to the exocytic pathway (6).  It is possible that both Group A compounds and 
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TORC1 signaling enhance sorting into an endosome-mediated exocytic transport route 
that is defective in the apl2∆ vps1∆ mutant.  TORC1 signaling and our compounds may 
in addition, or instead, downregulate an alternative transport route for invertase that is 
utilized by the apl2∆ vps1∆ mutant. 
! In addition to linking exocytic transport to signaling mechanisms that regulate 
growth, the identification of GTR2 as a suppressor of our Group A compounds was an 
exciting result, because it suggests that our chemical-genetic strategy may lead to 
insights about Avl9 function.  The gtr and avl9 mutants were among the top-ranked 
mutants in a genome-wide screen of the non-essential yeast gene deletion collection for 
mutants that are hypersensitive to both high hydrostatic pressure and cold temperature 
(3).  The reason for this growth phenotype of gtr an avl9∆ mutants is not clear, but it 
could reflect defects in traffic due to reduced membrane fluidity under these conditions.  
Other mutations in non-essential genes that cause defective transport from the Golgi 
were also identified in the screen (3).  Furthermore, at high pressure and cold 
temperature, the Tat2 permease is sorted to the vacuole even though TOR signaling 
seems unaffected (2), suggesting that the TORC1-regulated exocytic route is especially 
sensitive to conditions that reduce membrane fluidity. 
! Transcriptional profiles of S. cerevisiae subjected either to high hydrostatic pressure 
or to cold temperature indicate highly upregulated expression of genes involved in 
remodeling of the cell surface (plasma membrane and cell wall) under anaerobic growth 
conditions (1, 4, 10, 13, 28).  Traffic pathways or mechanisms that involve Avl9 and Gtr 
function may be involved in cell surface remodeling, and a defect in this process may 
lead to pressure- and cold-sensitivity.  Alternatively or in addition, the high levels of 
expression of these same set of genes encoding cell surface components may be toxic to 
the avl9∆ mutant.  The avl9∆ mutant is SLAM (synthetic lethality analysis on 
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microarrays) with mot3∆ (29), and Mot3 is a repressor of the expression of most of these 
same cell surface components (38).  It is also possible that Avl9 and Gtr proteins have a 
role in regulating plasma membrane homeostasis, or an Avl9- and Gtr-dependent 
sorting or transport process depends on optimized lipid composition.  There is much 
evidence that regulation lipid composition is critical for cargo sorting and transport 
carrier formation in the late secretory pathway (21, 23, 24, 30, 41). 
! The signaling pathways that regulate cell growth and proliferation are expected to 
coordinate with regulation of the traffic pathways that deliver cell-surface components 
and thereby mediate cell growth.  Therefore, our result that modulation of a TORC1-
mediated process is critical in the presence of our Group A compounds suggests that 
these compounds may serve as powerful probes for understanding the molecular 
mechanisms by which late exocytic transport is regulated in response to environmental 
factors.  Furthermore, a possible link to Avl9 function via Gtr2-mediated suppression of 
the drug effects, as well at the AVL phenotype conferred by the compounds, indicate 
that our new exocytic transport inhibitors may help us to discover the biochemical and 
biological functions of the Avl9 protein family.
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Chapter 3
A high-throughput screen for chemical inhibitors of 
exocytic transport in yeast
Work from this chapter was published in ChemBioChem, Vol. 11, p. 1291-1301 (2010) and 
reproduced here with permission from the publisher.
Introduction
! The signaling pathways that control cell proliferation must regulate the membrane 
and protein traffic pathways that are required for cell growth and cell division.  How 
these membrane traffic pathways are regulated, in particular at the late sorting steps of 
the exocytic pathway, is poorly understood.  Both the signaling pathways and exocytic 
routes are highly complex, resulting in numerous alternate mechanisms by which 
transport to the cell surface can be regulated.  The budding yeast, Saccharomyces cerevi-
siae, has proven to be a powerful model for understanding complex cellular processes, 
due both to the relative simplicity of this organism and the many tools available that 
take advantage of its genetic manipulability.  Yeast genetic studies played a major role 
in elucidating the basic signaling pathways by which cells respond to nutrient and other 
environmental conditions to regulate cell growth and proliferation [1, 2].  Furthermore, 
many of the components of the membrane traffic machinery were first discovered and 
characterized in yeast [3, 4].  However, the mechanisms by which cargo is sorted and 
packaged into transport vesicles in late exocytic compartments (Golgi and endosomes) 
is still not known.  This is in large part because we still need to identify the molecular 
machineries that carry out exocytic transport from the Golgi and endosomes, and we 
need to define the signaling mechanisms that regulate traffic from these organelles.  The 
goal of the present study was to identify molecular probes that hold promise to serve as 
powerful tools for both identifying and understanding the machineries that regulate 
and carry out late exocytic transport.  
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! The difficulty in identifying components of the late exocytic transport machinery is 
due to multiple exocytic traffic routes in both yeast and mammalian cells [5, 6], which al-
low cargo transport by alternate routes when a pathway is blocked [7].  Such ability of 
cells to overcome defects in late exocytic transport steps has made it difficult to identify 
the genes involved in mediating and regulating late exocytic transport, necessitating 
complex and laborious genetic screens [8].  An alternative and potentially more efficient 
strategy is a chemical genetic version of a successful classical yeast genetic screen that 
identified a novel component of the late exocytic transport machinery, Avl9 [8].  Here we 
describe such a chemical genetic screen, in which we identified small molecules that are 
novel secretory inhibitors.  Identifying the molecular and biological targets of these in-
hibitors will facilitate our understanding of late exocytic transport mechanisms, and 
how these mechanisms are regulated. 
Materials and Methods
Yeast strains and reagents
! The construction or origin of yeast strains used in this study are shown in Table 1.  
Strains were generated by crosses using standard yeast genetic techniques [26].  In some 
cases, sequential crosses were needed using progeny from the indicated parents in order 
to obtain the desired combined mutations.  The primary screen strains were JTY2953 
(snq2∆ pdr5∆) and an snq2∆ pdr5∆ vps1∆ apl2∆ strain derived from it, LZY35 (AID 738, 
739).  These strains are adenine auxotrophs (due to the ade2-101 allele, common in many 
laboratory strains).  In order to improve strain growth and to back-cross mutant strains 
into our wild-type background, new strains having wild-type ADE2 were constructed 
for use in all subsequent screening steps and assays.  These strains have primarily an
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Table 1.  Yeast strains used in this study.
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S288c background [27].  Additional strains were constructed to cross out a suc2∆ muta-
tion (deletion of the gene for invertase) to enable us to perform invertase secretion as-
says.  Strains were grown in YPAD medium:  Difco Bacto yeast extract (1%), Difco Bacto 
peptone (2%), and glucose (2%), supplemented with adenine hemisulfate (20 mg/L).  
Screening compounds (a ~97,000 compound library) were from the Molecular Libraries 
Small Molecule Repository.  All compounds were provided by BioFocus DPI in di-
methyl sulfoxide (DMSO, 100%) at a concentration of 10 mM. 
High-Throughput Screens
! Yeast strains were maintained as frozen glycerol stocks or on YPD agar plates (kept 
at 4°C for up to two weeks).  Two days before screening, ~4 colonies were inoculated 
into YPAD (50 mL) and grown at 30°C with aeration on a rotating platform (260 rpm) 
for 18-24 h to mid-exponential phase (OD600 0.5-0.9, read in a Genesys 5 spectropho-
tometer, Thermo-Spectronic Instruments).  This primary culture was inoculated into 
YPAD such that the secondary culture, grown at 30°C for ~20 h, was OD600 0.04 (strain 
JTY2953) and 0.1 (strain LZY35) at the time of plating for the screen.  This was done by 
first determining the growth rate of each screen strain, so that the secondary culture 
would not need to be diluted prior to plating, thus minimizing a lag in growth at the 
start of the screen.  The initial plating density of cells resulted in cultures nearing the 
end of exponential growth after ~18h growth in plates.
! For the primary screens (AID 738, 739), compound (7.5 nL) was added to YPAD me-
dium (1 µL) in 1536-well black, clear bottom plates (Corning), and secondary yeast cul-
ture (7 µL) was added to the plates for a final compound concentration of 10 µM and a 
final DMSO concentration of 0.1%.  Each plate contained control wells, with YPAD me-
dium containing DMSO (0.1%) serving as negative control and KU#7 (1.25 µg/mL), 
DMSO (0.1%) as positive control [16].  Liquid handling steps were performed with a 
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Biomek FX liquid handler (Beckman Coulter), a Multidrop Combi dispenser (Thermo 
Scientific), or an Echo 550 liquid handler (Labcyte).  After adding the yeast culture to all 
wells, the plates were incubated with lids (un-sealed), and inverted, at 30°C for 18 h in a 
humidified atmosphere.  Incubating the plates inverted maximized cell growth due to 
better access to oxygen, as the cells settled at the surface of the medium.  Following in-
cubation, the plates were slowly shaken before the reading at OD615 in an EnVision mul-
tilabel plate reader (PerkinElmer).
! For the dose response screens (AID  788, 789, 790), 320 compounds that selectively 
inhibited the growth of the vps1∆ apl2∆ mutant in the primary screen were retested in a 
10-point dose response assay.  Compounds were diluted in YPD medium to prepare a 
10x concentrated dosing solution (250 µM) from which a 10-concentration, 2-fold dilu-
tion series was prepared in YPD medium and added to 384-well clear plates (Corning) 
in 5 µL. The yeast cultures (strains LZY53, LZY80, LZY81 and LZY82) were grown as for 
the primary screen to generate an early-exponential phase culture, and yeast culture (45 
µL) was added to the plates with compounds for final compound concentrations be-
tween 0.05 µM and 25 µM, and a final DMSO concentration of 0.25%.  Positive and 
negative controls were as for the primary screen.  The plates were incubated at 30°C in a 
humidified atmosphere for 18 h, and OD615 was read in an EnVision multilabel plate 
reader. 
Data analysis for primary and dose-response screens
! All data from primary screens and dose-response assays were imported into Activi-
tyBase (IDBS) data management software for analyses.  For the primary screens, percent 
inhibition for both the control and mutant strains was calculated as: 100 x (1-(Median of 
test compound – Median of positive control)/Median of negative control – Median of 
positive control)).  Active compounds were those that showed ≥30% inhibition (30% is 
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the average compound % inhibition plus three times the standard deviation of com-
pound % inhibition).  Among the compounds chosen as having ≥30% inhibition, a hit 
was determined to be any compound that was significantly more toxic to the mutant 
test strain than to the control background strain.  Compounds that showed less than 
30% inhibition were defined as Inactive.  Compounds that were screened more than 
once and had both Active and Inactive outcomes were labeled Inconclusive.  For the 
dose-response screens, the percent inhibition of growth rate was calculated as: 100 x 
([growth rate DMSO-treated cells]-[growth rate compound-treated cells])/[growth rate 
DMSO-treated cells]. 
Secondary screens
! For secondary screening, 24 compounds from the 93 dose-response hits were reor-
dered from the original suppliers and subjected growth and secretion assays in mutant 
and background strains.  The first assay was a shaking-culture growth rate assay to de-
termine growth rates during exponential growth were measured.  Strains were grown in 
YPD overnight to exponential growth phase, and culture densities were adjusted to 
OD600 0.07 in YPD (8 mL), in 25x150 mm glass culture tubes.  Compounds were added 
at the indicated concentrations for a final volume of 10 mL and final DMSO concentra-
tion of 0.25%, and tubes were placed on a roller drum (Bellco) rotating at 50 rpm.  OD600 
readings were taken every two hours, for at least 4 readings to generate a growth curve.  
Rates were calculated from an exponential curve fit equation.  The correlation coeffi-
cient (Pearson r) was >0.9 in each case.  Secondary growth assays to generate growth 
curves were also performed in 96-well plates.  OD595 was read with a Model 680 micro-
plate reader (Bio-Rad) controlled by Microplate Manager software (Bio-Rad).  
! We tested selected hit compounds in two established secretion assays.  The first 
was an invertase secretion assay [3].  Cells were grown overnight to exponential phase, 
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then grown in YPD with high glucose (5%) for 2-3 hours on a roller drum at 50 rpm.  
Compound was added at the indicated concentration (or DMSO control, 0.25% final 
concentration), and cultures were grown for 15 min, followed by shifting cells to YPD 
with low glucose (0.1%) and compound or DMSO control for 90 min prior to perform-
ing the invertase secretion assay as described previously[8].  For slow-acting compounds 
(Figure 4E), the cells were grown in compound for 3h rather than 15 min prior to dere-
pressing invertase expression.  Invertase expression is repressed in high-glucose media, 
but upon shifting to low glucose, its expression is rapidly derepressed.  Therefore, all 
invertase expression and secretion occurs after compound addition.  As a second secre-
tory assay, we assayed for internal accumulation of an abundant cell wall protein, Bgl2, 
as described previously[8].  
Results and Discussion
! Most of the genes involved in membrane traffic were discovered by perturbing 
their functions either by mutations or with drugs [3, 9, 10].  We used a triple-synthetic-
lethal yeast mutant screen to identify a novel eukaryotic gene involved in exocytic 
transport, AVL9 [8].  This gene is essential in a mutant strain lacking a dynamin homo-
log, Vps1 [11, 12], and also lacking a subunit of the adaptor protein-1 (AP-1) adaptin com-
plex, Apl2, which is required for forming certain classes of clathrin-coated vesicles at the 
Golgi and endosomes [8, 13-15].  The apl2∆ vps1∆ double mutant has a block in an exocytic 
pathway but grows well because cargo is rerouted into a remaining pathway [8].  Muta-
tions or drugs that are lethal for the apl2∆ vps1∆ mutant but have little or no effect on 
wild-type cells are expected to cause a block in a remaining exocytic pathway.  We per-
formed a high-throughput phenotypic screen of a large library of drug-like compounds 
to identify small molecules that have such a mutant strain-specific effect.  An earlier 
screen produced only a few hits, likely due to the ability of yeast cells, like other fungi, 
to efficiently pump out a very broad range of structurally and functionally unrelated 
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compounds due to an abundance of ATP-binding cassette (ABC) transporters [16, 17].  S. 
cerevisiae has at least nine ABC pumps that are localized to the plasma membrane, and 
at least three of these, Pdr5, Snq2, and Yor1, are involved in pleiotropic drug resistance 
[17].  The most important of these are Pdr5 and Snq2, which have overlapping but also 
distinct specificities [18].  To increase the number and diversity of compounds in our 
phenotypic screen, we added the pdr5∆ and snq2∆ mutations to our vps1∆ apl2∆ strain. 
High-throughput screens for mutant-specific growth inhibitors
! Before screening the full compound library, we screened a subset of 10,000 com-
pounds for inhibition of growth of the test strain, vps1∆ apl2∆ snq2∆ pdr5∆ (LZY35).  The 
screen was performed in duplicate, in both 384- and 1536-well formats, to check repro-
ducibility of the assay and to confirm the appropriate screening parameters (data not 
shown, see PubChem Assay ID’s 636 and 637).  The Pearson’s correlation between the 
two runs (all 10,000 compounds) was a moderate 0.4, and the Minimum Significant Dif-
ference (MSD, denoting the variability between the two assays) was an acceptable 15.2% 
inhibition.  We then screened 97,519 compounds from the NIH Molecular Libraries 
Small Molecule Repository for compounds that selectively inhibit the growth of a vps1∆ 
apl2∆ snq2∆ pdr5∆ strain, when compared to the growth of the snq2∆ pdr5∆ background 
strain (Figure 1).  The screens were run in several batches on different days, with failed 
plates repeated.  Actives in the screen were defined as compounds that at 10 µM 
showed ≥30% inhibition in the assay (see details in Experimental Section).  Out of the 
compounds with an active outcome for the mutant strain, 320 that had an apparent se-
lective activity towards the vps1∆ apl2∆ snq2∆ pdr5∆ strain over the snq2∆ pdr5∆ control 
strain were reordered for a confirmatory dose response screen.
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Figure 1.  Summary of a high-throughput screen for identifying compounds that prefer-
entially inhibit the growth of a mutant strain having apl2∆ and vps1∆ mutations.  Pub-
Chem Assay ID’s (AID) are indicated for each screen step.
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Figure 2 (next page).  Summary of dose-response end-point growth assays for identify-
ing 93 hit compounds.  A) Structural clustering of compounds from the 93 hits.  Pub-
Chem SID’s for our designated SR numbers are shown in Table 2.  The SR number cor-
responds to the rank from the dose-response assay, with SR2 being the top-ranked com-
pound.  B) Data from the dose-response assays allowed grouping of compounds accord-
ing to specificity for mutants (PubChem AID 788, 789, 790).  The majority of our hit 
compounds were specific for the apl2∆ vps1∆ double mutant.  Among the top 56 con-
firmed compounds (ranked according to dose response growth assay), 13 compounds 
caused inhibition due to the vps1∆ mutation and were similarly toxic for the apl2∆ vps1∆ 
mutant; 12 compounds inhibited primarily the apl2∆ vps1∆ mutant but also had signifi-
cant effect on the apl2∆ mutant; and 31 compounds inhibited the growth of primarily 
the the apl2∆ vps1∆ double mutant with little or no effect on the apl2∆ or vps1∆ mutants.  
None of the top 56 compounds inhibited growth the apl2∆ vps1∆ mutant due only to the 
apl2∆ mutation.
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Table 2.  PubChem Substance ID for compounds referenced in this study.
71
Dose-response and secondary assays
! A 10-point dose-response assay with compound concentration ranging between 0.05 
µM and 25 µM was performed for the 320 compounds obtained from the primary 
screens, for each of the following strains, with the test-mutations indicated in bold: 
vps1∆ apl2∆ snq2∆ pdr5∆, vps1∆ snq2∆ pdr5∆, apl2∆ snq2∆ pdr5∆, and the snq2∆ pdr5∆ 
background strain (PubChem Assay ID’s 788, 789, and 790).  Of the 320 compounds 
tested in the dose-response assays, 93 confirmed as being selective for one of the three 
traffic mutant strains over the control strain.  Some of these compounds grouped into 
structural clusters (Figure 2A).  More than half of our 56 top-ranked hits from the dose-
response growth assays required both the vps1∆ and apl2∆ mutations for significant 
growth-inhibitory activity, consistent with the rationale for the design of our chemical 
genetic screen (Figure 2B).  However, some compounds had activity due to the vps1∆ 
mutation alone (with no increase in effect on the apl2∆ vps1∆ strain).  Other compounds 
significantly affected the growth of the apl2∆ mutant and not the vps1∆ strain; however, 
all of these had greater activity on the apl2∆ vps1∆ strain, indicating more robustness in 
Apl2-mediated processes.  The different mutant-specificities of our hit compounds indi-
cate that they have unique molecular and biological targets.
! Of our 93 hit compounds from the dose-response growth assay, 24 compounds were 
chosen for follow-up studies based on:  1) significant selectivity towards the vps1∆ apl2∆ 
strain over the background strain;  2) representatives of major structural clusters among 
the identified hits;  3) preference for being active for the vps1∆ apl2∆ mutant over one of 
the single traffic mutants, but with representatives of each class selected; and 4) chemi-
cal tractability.  We named these compounds “SR#,” and they are listed, along with 
other compounds referenced here, in Table 2.
! As our first secondary assay, we retested growth in shaking exponential-phase cul-
tures, in presence of compound compared to DMSO control.  Whereas the dose-
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response end-point growth assays were performed in 384-well plates, non-shaking, over 
~18 h of growth, the shaking cultures had greater aeration, allowing faster growth, and 
were assayed only during ~9 h of exponential growth phase (see Experimental Section).  
Some of the compounds did not show confirmed activity in the shaking-culture assay, 
likely because they were slow-acting, and therefore would have observable activity over 
18 h, with just one end-point measurement taken, but not in the first few hours of expo-
nential growth.  Alternatively, some compounds could be more active in lower-oxygen 
conditions or on slower-growing cells in plates.  The shaking-culture secondary screen 
was repeated with strains having only either the pdr5∆ or only the snq2∆ mutation, to 
test which drug pump mutation was more critical for compound effect (Figure 3A).  Ef-
fectiveness of compounds in the presence of just one of these pump mutations was de-
sired because we noticed a drop in growth rate of the vps1∆ apl2∆ mutant when both 
drug pump mutations were crossed into the strain.  In contrast, effect on growth was 
much less when just one ABC transporter was deleted (Figure 3B), indicating that in-
cluding just one of these deletion mutations would minimize growth defects or other 
phenotypes due to pump mutations in our subsequent assays.  We found that the pdr5∆ 
mutation was the more critical one for sensitizing our strain to almost all of the 24 com-
pounds we tested (Figure 3A).  This mutation had no effect on the growth of an apl2∆ or 
a vps1∆ strain, which had a similar growth profile as the pdr5∆ background strain; how-
ever, the apl2∆ vps1∆ pdr5 triple mutant did have some growth defect (Figure 3C).  We 
performed our remaining secondary assays using just the pdr5∆ mutation in all strains 
(wild-type for SNQ2). 
! Our largest structural group from the 93 compounds identified in the dose-response 
assays is shown in Figure 4A.  Two of these compounds fall into Cluster 1 (Figure 2A), 
and three-dimensional overlay of all five compounds in this group shows that they have 
very similar structures (Figure 4B).  The dose-response growth assays for these com-
pounds indicated that they were all highly specific for the vps1∆ apl2∆ mutant, with 
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Figure 3 (next page).  Exponential-growth-rate assays of mutant and background 
strains. A) Shaking-culture growth assays showed that the pdr5∆ mutation is sufficient 
for sensitizing yeast strains to most of the compounds (at 20 µM) identified as hits in 
our dose-response assay.  Rates were determined from the equation of an exponential 
curve fitted to the exponential growth curve of each strain (correlation coefficient >0.9) 
and shown as a percent of the rate without compound added.  Each compound is at 5 
µM.  The sequence of SR numbers corresponds with ranking in the dose-response 
growth assay, with SR2 being the highest-ranked hit.  SR numbers are color-coded ac-
cording to mutant specificity, as determined by dose-response assays (PubChem AID 
788, 789, 790).  Corresponding PubChem SID’s are shown in Table 2.  B) The pdr5∆ and 
snq2∆ mutations confer a growth defect on a vps1∆ apl2∆ strain, which is most pro-
nounced if both pdr5∆ and snq2∆ mutations are present and least-pronounced with 
pdr5∆.  Rates were determined as in (A).  C) Microwell-plate exponential growth curves 
of strains having a pdr5∆ mutation.  Strains for A-C are as follows:  LZY109 (snq2∆); 
LZY108 (pdr5∆); LZY96 (apl2∆ vps1∆ snq2∆); LZY104 (apl2∆ vps1∆ pdr5∆);  NY10 (wild-
type = “wt”); LZY53 (snq2∆ pdr5∆); EHY644 (apl2∆ vps1∆); LZY82 (apl2∆ vps1∆ snq2∆ 
pdr5∆ = “quad”); LZY119 (vps1∆ pdr5∆) and LZY120 (apl2∆ pdr5∆).
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Figure 4 (next page).  The largest structural group of hit compounds had greatest speci-
ficity for the apl2∆ vps1∆ mutant for inhibiting growth and secretion.  A) Compound 
structures with SR# and PubChem SID.  B) 3-dimensional overlay of the five com-
pounds shown in (A), with carbons in each compound colored as the SID #.  C) Dose-
response end-point growth assay for SR5.  The yeast strains are LZY53 (background); 
LZY81 (vps1∆); LZY80 (apl2∆); and LZY82 (vps1∆ apl2∆); all four strains have snq2∆ 
pdr5∆ mutations.  D) Microwell plate growth curves for SR5 (compare to Figure 3C).  E) 
Invertase secretion assay for SR5 shows a secretion defect specific for vps1∆ apl2∆.  
Strains are as in Figure 3C.  The means of three experiments (from three independent 
cultures) are shown.  Error bars, SEM.  F) Strain LZY104 (apl2∆ vps1∆ pdr5∆) grown in 
microwell plates, in either 2.5 µM SR5 or DMSO control.  There is no growth defect until 
~4h after adding compound.  
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smaller effect on the growth of vps1∆ or apl2∆ mutants.  Figure 4C and D show growth 
assays for SR5, the highest-ranked compound in this group.  Furthermore, an assay for 
invertase-secretion (see Experimental Section) showed that SR5 has an inhibitory effect on 
secretion that was specific for the vps1∆ apl2∆ mutant and not detected in the other 
strains (Figure 4E).  However, we also found that these compounds were relatively 
slow-acting, with little effect on growth until ~4h of exponential growth (Figure 4F).  
This suggests that these compounds may affect signaling pathways that regulate gene 
expression, or they may need to build up a toxic effect (although higher and lower con-
centrations of compound showed a similar delay in effect; not shown).  
! Another compound of interest is SR28 (Figure 5A), which did not fall into a struc-
tural group from our 93 hits.  Dose-response and growth-curve analyses indicated that 
this compound affects primarily vps1∆ (and therefore also the vps1∆ apl2∆ mutant).  This 
compound is of significant interest because it causes a very severe, rapid block in inver-
tase secretion (Figure 5D).  Although the greatest effect on secretion is seen in the vps1∆ 
strain, at higher concentrations there is also significant effect on the apl2∆ and back-
ground strains (Figure 5D).  Likewise, SR28 caused a significant internal accumulation 
of the cell wall protein, Bgl2, which at steady-state is normally almost entirely in the cell 
wall (Figure 5E).  Interestingly, the background strain also had slight internal accumula-
tion of Bgl2 at the 30 min time point after adding compound, but this accumulation did 
not increase, and even decreased slightly, with longer time points, suggesting that the 
background strain was able to adapt to the transport defect, perhaps by upregulating an 
alternate transport route that is blocked in the mutant strain.
! Another compound that had a significant and rapid effect on invertase and Bgl2 se-
cretion is SR9 (Figure 6).  We tested structurally similar compounds, and found one 
compound with very similar activity, having PubChem Compound ID 656067 (Figure 
6A).  The dose-response end-point growth assay for SR9 indicated that all growth ef-
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fects were due to the vps1∆ mutation, and this was consistent both in our exponential 
growth curve assays and invertase secretion assays, which likewise showed vps1∆-
specific effects (Figure 6B-D).  SR9 was of interest also because unlike the majority of the 
other hits that we tested, it had a significant effect on secretion even in PDR5 SNQ2 
strains (wild-type for drug pumps; not shown), making it more promising in future 
genome-wide screens for identifying the molecular and biological targets of the com-
pound.
! A group of compounds with similar structures that also did not require pump muta-
tions for effects on growth is shown in Figure 7A.  Some of these compounds fell into 
Cluster 2 (Figure 2A).  Additional hit compounds that are similar to these are shown in 
Figure 7B.  The compounds in Figure 7 were among  the highest-ranking hits from our 
dose-response growth assays for potency and selectivity for the vps1∆ apl2∆ strain, with 
some activity for the apl2∆ strain, and little or no effect on either vps1∆ or the back-
ground strain (Figure 7C, D).  The lack of effect on the vps1∆ strain differentiates these 
compounds from others that we analyzed in detail (Figures 5-7), so it is likely that they 
have a different molecular and biological target than those of the other hits.  Interest-
ingly, these compounds were effective primarily in rich media (YPD), with little effect in 
minimal (synthetic) media (such as CSM) (our unpublished observations).  This effect of 
media is interesting because it resembles the phenotype of yeast ras mutants as well as 
mutants of the yeast synaptobrevin homologs, which function in targeting exocytic 
vesicles to the plasma membrane[19].  We also found that the compounds were slow-
acting, and therefore difficult to analyze in our transport assays.  Like the compounds in 
Figure 4, they may affect signaling pathways that respond to transport blocks by regu-
lating gene expression.
! Many of the 24 compounds selected for secondary assays did not block invertase se-
cretion in our assays.  Some of these compounds may have a delayed effect and block 
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Figure 5 (next page).  SR28 was the most potent secretory inhibitor obtained from the 
screen.  A) Structure of SR28.  B) Dose-response end-point growth assay for SR28.  C) 
Microwell plate growth curves for strains grown in 5 µM SR28.  D) Invertase secretion 
assay for strains grown in 2 µM or 5 µM SR28.  All strains had a secretory defect in this 
compound, and the defect was most severe for the vps1∆ and vps1∆ apl2∆ mutants.  The 
means of three experiments (from three independent cultures) are shown.  Error bars, 
SEM.  E) Western blots showing the accumulation of internal Bgl2 in 5 µM SR28 at the 
indicated times.  Bgl2 is almost entirely in the cell wall at steady state, so the internal 
accumulation of this protein can be detected by removing the cell wall.  PGK (a cyto-
plasmic protein) is shown as a loading control.  Strains are as in Figure 3C.
80
81
Figure 6 (next page).  SR9 is a vps1∆-specific growth and secretory inhibitor.  A) Struc-
ture of SR9 (left) and an analog (right) with similar activity.  B) Dose-response end-point 
growth assay for SR9 (strains as in Figure 4C).  C)  Microwell plate growth curves for 
strains grown in 5 µM SR9 (strains as in Figure 3C).  D) Invertase secretion assay for 
strains grown in 5 µM SR9.  The secretory defect is dependent entirely on the vps1∆ mu-
tation.  The means of three experiments (from three independent cultures) are shown.  
Error bars, SEM.  E) Western blots showing accumulation of internal Bgl2 after growing 
strains in 5 µM SR9 for the indicated times.  PGK is a loading control.
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Figure 7.  Cluster 2 and similar compounds were highly selective for the vps1Δ apl2Δ 
double mutant. A) Structures for two Cluster 2 and one closely related compound. B) 
Additional compounds that resemble Cluster 2 compounds.  C) The Cluster 2 com-
pound, SR2, ranked highest in our dose-response screen. It is highly selective for inhib-
iting the growth of the apl2Δ vps1Δ double mutant in microwell plates (shown) and agar 
plates (not shown).   D) Compounds shown in (B) were also specific for the vps1Δ apl2Δ 
mutant. Yeast strains are as in Figure 3C.
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secretion at a later time point.  Alternatively, they may have vps1∆ apl2∆ mutant-specific 
toxicity that is not due to blocking exocytic transport.  Recent studies have suggested 
that traffic mutants are particularly prone to drug hypersensitivity, perhaps because 
they are defective in trafficking of drug transporters that function in detoxification ei-
ther at the cell surface or at the vacuole [20, 21].  However, we would expect a larger num-
ber of hits if our screen merely identified toxic substances due to a general drug-
sensitivity of our test strain.  Analysis of screen results submitted by others to PubChem 
suggests that our compounds were highly specific for our screen, in particular at the 
dose-response or confirmatory steps, again arguing against general drug-sensitivity of 
our screen strain.  Furthermore, because both the vps1∆ apl2∆ mutant and control back-
ground strain had a significant defect in detoxification due to the pdr5∆ snq2∆ muta-
tions, neither test nor control strain could efficiently eliminate drugs, so most of our hits 
likely target a process that is relevant to membrane traffic function.  Therefore, even 
compounds that do not rapidly block secretion are of potential future interest.  For ex-
ample, they could trigger signaling mechanisms that shut down growth in response to 
traffic defects.
Conclusions
! Using a high-throughput phenotypic screen, we identified 93 compounds that spe-
cifically affect the growth of a mutant strain blocked in one branch of the exocytic 
pathway.  Our analysis of selected compounds from these hits indicates that at least 
some of our mutant-specific growth inhibitors are novel secretory inhibitors that likely 
affect a transport pathway that remains functional in the mutant in the absence of 
drugs.  Therefore, further analysis of our hits is expected to identify additional traffic 
inhibitors.  
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! Identifying the molecular targets of our inhibitors, as well as biological effects in 
genome-wide fitness assays [22, 23], will contribute to a better understanding of the 
mechanisms that mediate late exocytic transport.  Some of our compounds are expected 
to target Avl9 or an Avl9-related process, since they generate an AVL (apl2∆ vps1∆ le-
thal) phenotype, similar to that of avl9∆ [8].  Avl9 is a conserved, ancient eukaryotic pro-
tein and a member of a novel superfamily of ancient paralogs, most of which have not 
been studied in any organism [8].  Therefore, the hits identified in our HTS assay may 
serve as useful tools for discovering a potentially novel function mediated by Avl9 and 
its homologs.  Prior to seeking the targets of our new inhibitors, we may need to opti-
mize our compounds by testing analogs for potency as well as specificity for the traffic 
mutant strains.  The possibility of non-specific effects is common to all small molecule 
screens, whether the screens involve in vitro assays or a cell-based phenotypic assay 
such as ours [24].  However, low-specificity compounds would be expected to be simi-
larly toxic to the background control strain in our assays.  Therefore, some of our hits 
should have sufficient specificity for simple screens that could help to identify potential 
target(s), for example a gene-dosage screen [25]. 
! Although some of our hit compounds may have pleiotropic effects, mutations like-
wise can have pleiotropic effects, and specificity of effect is not necessarily a greater 
concern with small molecules than it is with mutants as tools to study gene function.  
For example, most bioactive small molecules do not primarily affect protein target lev-
els, whereas many mutations do affect protein abundance, causing pleiotropic effects 
especially in cases where the protein is normally a part of a complex [24].  Furthermore, 
our chemical genetic strategies are likely to identify genes that would be difficult or im-
possible to identify by the classical genetic mutant screen that identified Avl9.  For ex-
ample, gene mutations that result in very severe growth phenotypes even in the pres-
ence of APL2 and VPS1, or which have only sickness rather than lethal phenotypes 
when their functions are blocked in the screen strain background, would not be so read-
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ily identified in the mutant screen.  Therefore, our chemical genetic strategy is a valu-
able complement to classical genetics for understanding the mechanisms and regulation 
of late exocytic transport.
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Chapter 4
Conclusions and Future Directions
Despite the enormous advances in the membrane traffic field in the past three 
decades, the mechanisms of exocytic transport from the Golgi and endosomes have 
remained elusive.  This is due primarily to the complexity of the post-Golgi traffic 
pathways (9-10).   The goal of my doctoral thesis was to contribute towards 
understanding how cargo is transported to the cell surface, and how this process is 
regulated.  My strategy involved chemical genetic screens, in which we identified novel 
inhibitors of the late exocytic pathway (23-24).  I discovered that one of these inhibitors, 
KU7, can be suppressed by over-expressing GTR2.  This gene encodes a small GTPase 
that regulates the traffic of an amino acid permease and the activity of a major regulator 
of growth, TORC1 (23).  My results indicate that the chemical genetic strategy is useful 
for discovering components and regulators of the late exocytic transport machinery.  
Another contribution of my thesis work is helping to establish a link between Gtr2 
and Avl9 function in the late secretory pathway.  The avl9∆ mutation is lethal in an apl2∆ 
vps1∆ background (11).  Likewise, our secretory inhibitors have an "AVL" phenotype, 
meaning that they are especially toxic or lethal in an apl2∆ vps1∆ background (23-24).  
Therefore, some of the inhibitors could inhibit Avl9, or they could inhibit a process that 
is somehow connected to Avl9 function.  Prior to my work, there was already a hint that 
Avl9 and Gtr2 may have a related function, because both GTR2 and AVL9 had been 
identified together in a genome-wide screen for genes important for survival under 
high pressure and in the cold (2).  AVL9 and GTR2 were among the very top-ranked 
mutants in that screen, and very few other phenotypic screens have identified either 
AVL9 or GTR2.  However, the cold/pressure sensitivity screen identified genes in a 
93
wide range of functional classes, so that screen alone did not indicate a strong 
functional link between the genes.  Because increased GTR2 expression suppresses a 
traffic-related defect caused by KU7, and KU7 causes a traffic defect that is related to 
Avl9 function, it is possible that both Avl9 and Gtr2 function together to regulate traffic 
by a mechanism that is sensitive to cold and high pressure.  Alternatively, Avl9 and Gtr2 
may regulate the traffic of cargo that protect cells from environmental stress such as 
cold and high pressure.
Only a few traffic-related genes were identified in the cold/pressure sensitivity 
screen.  Gtr2 is part of a complex that sorts an amino acid permease at endosomes 
depending on nutrient conditions (7).  Other members of this complex are encoded by 
genes that were also identified as cold/pressure sensitive (2).  In addition, the cold/
pressure sensitivity screen identified DRS2, which encodes for an aminophospholipid 
translocase (flippase) important for the formation of clathrin-coated vesicles (4; 6).  This 
suggests that regulation of membrane lipid composition may be the key traffic-related 
factor that is sensitive to the physical environment.  Many genes that regulate lipid 
composition are either highly redundant or essential for viability.  Essential genes 
would not have been identified in the screen by Abe and Minegishi, because that screen 
made use of the haploid collection of yeast gene deletion mutants, so this could explain 
why they did not identify many lipid regulators in their screen.  They also did not 
include mutants that were very sick even under normal growth conditions.  Although 
Avl9 and Gtr2 function may be sensitive to lipid composition, neither protein is likely to 
be directly involved in regulating membrane lipids.  This is because a large genome-
wide genetic interaction study did not link either Avl9 or Gtr2 closely to this function 
(5).  So, Avl9 and Gtr2 may regulate a traffic pathway that is especially sensitive to 
membrane composition.  The proper sorting of some nutrient permeases is very 
sensitive to high pressure as well as to altered membrane lipid composition (1; 20).  In 
the future, we plan to examine whether Avl9 has a function in trafficking nutrient 
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permeases, as has already been shown for Gtr2 (7).
Another function of Gtr2, along with Gtr1, is regulating the activity of TORC1 in 
response to amino acids (14; 19).  TORC1 is a major regulator of cell growth, and cell 
growth requires the exocytic pathway for transporting membranes and proteins to the 
cell surface.  Therefore, Gtr2 and possibly Avl9 may link TORC1 activity to regulating 
the late secretory pathway for growth.  When nutrient conditions are poor, it is 
important to downregulate an exocytic pathway that promotes growth, and when 
nutrient conditions are optimal, then growth-promoting exocytosis should be increased.  
Under nutrient-poor conditions, another traffic pathway, autophagy, is increased in 
order to recycle nutrients, and this is in part regulated by TORC1 (reviewed in (21)).  
Recent evidence from our laboratory showed that Avl9 has a regulatory role in 
autophagy (unpublished results).  Therefore, a future research direction is to determine 
whether Avl9 and Gtr proteins regulate the balance between the exocytic and autohagic 
pathways, both of which require traffic from late Golgi compartments and possibly 
endosomes (8; 15).
The biochemical function of Avl9 is still not known, so we do not know exactly how 
it is related to Gtr2 function or traffic regulation.  Avl9 is a member of an ancient 
eukaryotic protein family (11), one branch of which has recently been shown to encode 
for Rab GEF's (3; 22).  However, Avl9 was not found to function as a GEF for any Rab 
tested (22).  This suggests the possibility that the Avl9-branch of the superfamily also 
functions as a GEF but for another type of small GTPase.  The link of Avl9 and Gtr2 
suggests that perhaps Avl9 is a GEF for Gtr2.  However, my work suggests that this is 
very unlikely.  AVL9 and GTR mutants have different phenotypes:  I found that unlike 
gtr2∆ or gtr1∆, the avl9∆ mutant is not sensitive to the TORC1 inhibitor rapamycin (my 
unpublished results).  This is in contrast to the result from genome-wide analysis by 
others, which indicates that avl9∆ homozygous diploid is rapamycin sensitive, but we 
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found that there is a problem with the avl9∆ mutant used in many genome-wide 
studies.  Also, as shown in Chapter 2, I found that the gtr2∆ mutation is not lethal in 
combination with vps1∆ apl2∆ double-mutation.  More recently, I found that gtr1∆ vps1∆ 
apl2∆ as well as the quadruple mutant, gtr1∆ gtr2∆ vps1∆ apl2∆, likewise have only a 
small growth defect and are viable (my unpublished results).  In contrast, the avl9∆ 
vps1∆ apl2∆ triple mutant is not viable (11).  Furthermore, overexpression of AVL9 is 
highly toxic (11), and I found that this toxicity is not rescued by the gtr2∆ mutation.  
Although my results do not entirely rule out the possibility that Avl9 has GEF activity 
for Gtr2, this cannot be the primary function of Avl9.  Most likely, Avl9 functions as a 
regulator of another GTPase, and future experimental analysis of Avl9 function will 
help to identify that GTPase.  
Discovering the targets of some of our new secretory inhibitors promises to reveal 
more about Avl9 and Gtr function, and this is an important area for our future research.  
One very promising strategy for target identification, which can indicate both the 
biological function being targeted and hint at the specific molecular target, is parallel 
analysis of fitness, and this is the method we plan to use.  In this method, pools of yeast 
gene deletion mutants are grown in the presence of a compound, and the cultures are 
then assayed to determine which mutants have reduced fitness under these conditions, 
compared with fitness in the absence of compound (12; 17).  In the heterozygous gene 
deletion strain collection, the compound target may be revealed, because if there is only 
one copy of the gene for the target, the mutant would likely have reduced fitness.  In a 
haploid or homozygous diploid collection (nonessential genes only), the biological 
function being targeted can be revealed.  Our compounds are somewhat toxic even in 
wild type cells, so it should not be necessary to include the vps1∆ or apl2∆ mutations to 
see effects on fitness, which is assayed after many generations of growth and does not 
require a high level of toxicity.  There are additional strategies for compound target 
identifications, including more direct methods that assay for physical interaction 
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between compounds and targets, but such methods generally require strong, stable 
interactions and are often not successful (13; 16; 18).  These methods could be used in 
combination with the chemical genomics strategy described above.
! In summary, my thesis work shows that our new compounds promise to serve as 
tools to study the exocytic transport process, and they will help us to learn more about 
Avl9 and Gtr2 function.  My work also provides an example of how chemical genetic 
strategies can serve as helpful complements to classical genetics (mutant screens and 
genetic interactions) for understanding complex cellular processes.  Similar yeast 
chemical genetic screens should be useful in other areas of cell biology.  Our work will 
contribute to future screens because we have optimized compound library screening 
with yeast cells.
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